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Protein-structured pharmaceuticals have become very important for treating several 
chronic and acute illnesses, but their commercialization is sometimes impeded by their poor 
stability in aqueous solutions. In some cases, protein stability may be better in dry than in 
aqueous formulations, and freeze drying (lyophilization) is the most commonly used method 
for manufacturing such products. However, excipients are needed to keep proteins from 
degrading during processing and storage, and the current selection of stabilizing compounds 
accepted by the regulatory authorities is limited. The aim of this thesis was to compare the 
stabilizing efficacies of different disaccharides and polyalcohols in protein formulations. 
Firstly, the efficacies of 11 disaccharides and polyalcohols as -galactosidase-protecting 
compounds were characterized at three different concentrations. Disaccharides were 
generally more effective than polyalcohols, which appeared to be caused in some cases by 
their lower crystallization tendency. Four disaccharides (cellobiose, melibiose, sucrose and 
trehalose) were selected for further secondary structure stabilization studies, which 
corroborated the results of the activity analysis studies that the protein-protecting efficacies 
of trehalose and melibiose differed from those of sucrose and cellobiose. 
Secondly, the water plasticization and crystallization properties of the four 
disaccharides were studied after freeze drying by storing them at different relative humidity 
atmospheres. Cellobiose and sucrose were shown to crystallize faster and at lower relative 
humidity than trehalose and melibiose. The water plasticization properties of sucrose were 
shown to differ from the other disaccharides. Melibiose was most stable of the four 
compounds in amorphous state, which may have partly been caused by its slower molecular 
relaxation rate compared to trehalose. 
Thirdly, the effect of freeze drying parameters on polyclonal IgG stability was studied in 
order to find out how much the stability of such antibodies could be affected by processing 
conditions in formulations containing trehalose. While varying the primary drying pressure 
and secondary drying heating rate did not directly affect protein stability, increased 
aggregation did occur at lower primary drying pressures when sodium phosphate buffer was 
used in the formulation. This may have been caused by buffer freeze-concentration, which 
may have been more significant when the sample temperature was lowered below the glass 
transition temperature of the freeze-concentrated phase. Sodium chloride was also shown to 
reduce the Z-average diameter of the rehydrated polyclonal IgG lyophilizates, which may 
have been caused by a decrease in protein aggregation. 
Finally, the efficacies of trehalose and melibiose in protecting a monoclonal antibody 
(rituximab) from degradation during freeze drying and storage at different relative humidity 
atmospheres were compared by storing the lyophilizates up to 3 months. Melibiose was 
generally more effective than trehalose in inhibiting secondary structure alterations, 
fragmentation and aggregation during drying and storage. Storage at dry conditions (RH 5%) 
was shown to be more harmful for rituximab in the lyophilized formulations than storage at 
more humid conditions (RH 11-23%), which may have been caused by the susceptibility of 
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Proteins are inherently unstable molecules. One of the main reasons for this is that 
compared to small organic molecules, proteins are significantly larger and more complex in 
structure. When putting this into perspective in the case of drug molecules, it says something 
about the enormous size of proteins that the mass of rituximab (a monoclonal antibody with 
Mw =  144  000  g/mol)  is  roughly  700  times  that  of  the  mass  of  ibuprofen  (a  common  non-
steroidal anti-inflammatory drug with Mw =  206  g/mol),  whereas  the  mass  of  the  Earth  is  
"only" about 80 times that of the Moon. While an increase in size does not automatically 
cause stability issues for different molecules, it does tend to amplify their structural 
complexity, which in turn may increase the number of relevant degradation pathways. 
When using proteins as active pharmaceutical ingredients (APIs), their bioactivity is 
dependent not only on their primary amino acid sequence, but on their three dimensional 
structure as well. Structural alterations in the native conformation of pharmaceutical 
proteins, such as monoclonal antibodies (mAbs), can lead to loss of therapeutic activity and 
increased immunogenicity (Wang et al., 2010). Therefore, issues with protein stability during 
processing and storage may impose a significant bottleneck for the commercialization of 
protein-structured pharmaceuticals (Randolph and Carpenter, 2007). However, there is 
much commercial interest in the production of stable protein-structured APIs, since they 
offer significantly improved therapy options compared to small-molecule compounds.   
One possible method of increasing the storage stability of a protein formulation is to 
dry it, but this is not usually the most preferred option. This is because the process is 
expensive and it may even degrade the product if not done correctly, which means that if a 
protein is sufficiently stable in aqueous solution, it is not normally dried. However, in some 
cases a sufficient shelf life (preferably 2-3 years at 2-8°C) cannot be achieved if the protein is 
formulated as an aqueous solution. Another drawback of aqueous formulations is that they 
must be stored as refrigerated or frozen, whereas drying can in some cases allow the product 
to be stored in room temperature. Furthermore, shipping aqueous protein solutions can be 
detrimental to the product, as shaking subjects proteins to an increased air/water interface 
due to bubble formation and may result in aggregation (Mahler et al.,  2005). Mostly due to 
these factors, drying the protein formulation is sometimes a justifiable stabilization strategy.  
Freeze drying (lyophilization) is the most common method of drying therapeutic 
proteins, but it requires careful formulation when choosing the correct excipients and 
designing the drying cycle (Wang, 2000). Still, it may often be the most feasible way of 
stabilizing certain proteins, so it remains an important, albeit expensive and time consuming, 
production method for biopharmaceutical drug products. Disaccharides such as trehalose 
and sucrose are commonly employed as protein-protecting excipients in marketed 
lyophilized drug products (Wang et al., 2007), but other disaccharides have not been 
frequently used. With an ever growing number of protein-structured pharmaceuticals in 
research pipelines, the need for new stabilizing excipients is likely to grow too. 
This thesis focuses on improving protein stability during freeze drying and the 
subsequent storage. Emphasis is placed on comparing the use of disaccharide- and 
polyalcohol-structured excipients that are already used in biopharmaceutical drug products 
to those that are not currently included in any marketed products. The work aims to bring 
insight into protein stabilization mechanisms during processing and storage by first using 
two nontherapeutic model proteins in the studies. This knowledge will then be put into 
practice, when an attempt will be made to produce lyophilized formulations that are stable 





2 Literature overview 
 
 
2.1 Protein structure and therapeutic proteins 
 
2.1.1 Protein structure 
The backbone of human proteins consists of up to 20 different naturally occurring 
amino acids that are linked together by peptide bonds. Given that a single protein may weigh 
several hundred kilodaltons, and that other molecules such as carbohydrates may also be 
attached to the peptide backbone as side chains, there is practically an endless number of 
protein structures available. The order, or sequence, in which the amino acid are arranged is 
often referred to as the primary structure of the protein (Branden and Tooze, 1999), and an 
example of a simple primary structure is shown in Figure 1. What makes the structural 
diversity of proteins even more complex, however, is that their biological activity is 
dependent not only on their amino acid sequence, but their three-dimensional structure as 
well. The primary structure adopts simple energetically favourable three-dimensional forms, 
known as secondary structures, based on the sequence of amino acids and several kinds of 
intramolecular bonds such as hydrogen- and covalent bonds (Fig. 1). Common secondary 
structures include -helices, -sheets and –turns, and sometimes a large part of the protein 
may appear randomly oriented as well. Adjacent secondary structures may carry out simple 
biological functions, such as acting as binding sites for other molecules. The overall three-
dimensional structure of a single polypeptide chain is known as its tertiary structure, and it 
may possess several active sites with different biological functions (Fig. 2). Furthermore, 
multimeric proteins that consist of several polypeptide chains are said to possess an 
additional quaternary structure (Fig. 2), where individual tertiary structure subunits may 




Figure 1. Above: Primary structure of the tripeptide serylglycylleucine (R-groups marked 
with gray); Below: -helix (left) and -sheet (right) secondary structures, with hydrogen 






Figure 2. Left: Tertiary structure of protein G of Streptococcus sp. G148 according to 
Butterworth et al. (1998); Right: Quaternary structure of -galactosidase sucrose-kinase 
according to Bruel et al. (2011), where individual polypeptide chains are coloured with 
different colours. The images have been obtained from The Protein Databank in Europe 
(PDBe, http://www.ebi.ac.uk/pdbe/).  
 
The so-called native state of a protein, which represents its folded and biologically most 
commonly observed structure, is not a rigid unit, but a dynamic system which continuously 
fluctuates between a limited number of conformations (Jaenicke, 1991). In an aqueous 
solution, the most energetically favourable conformations are usually formed when the non-
polar protein side-chains are directed against each other, forming a hydrophobic core that is 
surrounded by a polar (hydrophilic) surface (Branden and Tooze, 1999). In addition to the 
hydrophobic/-philic forces, protein conformation is further stabilized by intramolecular 
bonds, such as hydrogen bonds and disulphide linkages between different polypeptide chain 
segments. To cause a change in the three-dimensional conformation, a protein must either be 
subjected to an energy that exceeds the activation enthalpy of unfolding, or its surroundings 
must be altered in such a way that the previous native conformation is no longer the 
energetically most stable one. 
 
2.1.2 Therapeutic proteins 
Therapeutic proteins are proteins that can be used to treat or prevent illness in 
patients. Due to their more complicated three-dimensional structure, they are often 
differentiated from therapeutic peptides, which are sometimes defined as smaller 
polypeptide chains comprising of < 50 amino acid residues (Vlieghe et al., 2010). By 
following this classification, it can be estimated that the number of therapeutic proteins or 
protein fragments (discounting vaccines) that are or have at one point been marketed in the 
US, Europe and/or Japan is now over 130. Protein-structured API are used to treat myriad of 
clinical conditions, ranging from simple gastrointestinal (GI) tract lactase enzyme deficiency 
(lactose intolerance) to more serious illnesses, such as diabetes, blood clotting disorders and 
different forms of cancer. A major factor limiting the peroral administration of therapeutic 
proteins has been their modest permeation through biologic barriers, such as epithelial cell 
layers, as well as their instability in the presence of the protein-catabolizing enzymes of the 
GI-tract. Therefore, protein-structured APIs have thus far mostly been administered 
parenterally. However, pharmaceutical companies have been eager to search for alternative 





example is insulin, which has been marketed as a dry powder inhalation (Exubera®, Pfizer 
Inc., NY, USA, discontinued in October 2007) and has recently been clinically tested as a 
peroral formulation by several companies (Akkati et al., 2011), such as Biocon Ltd. 
(Bangalore, India) and Novo Nordisk A/S (Bagsvaerd, Denmark). 
One of the most important therapeutic protein groups is certainly antibodies. This is 
because they can be engineered to bind to specific substrates, as well as conjugated to other 
therapeutic molecules in order to increase their efficacy and reduce the dose needed to 
produce a therapeutic effect (Wang et al., 2007). The development of therapeutic antibodies 
has advanced in leaps ever since Köhler and Milstein (1975) developed a method for 
producing monoclonal antibodies (binding to only one specific epitope) by in vitro cell 
fusion. The first mAb drug product, Orthoclone OKT3® (Janssen-Cilag Ltd., 
Buckinghamshire, UK), was approved for market in 1986 (Wang et al., 2007), and in late 
2012, 32 mAb drug products had received a marketing authorization (discounting diagnostic 
products). The therapeutic scope of antibodies is broad, ranging from the treatment of 
autoimmune diseases such as Crohn’s disease and rheumatoid arthritis to cancerous and 
infectious diseases, as well as transplant rejection therapies. In 2011 five out of the top 20 
drug products by sales were mAbs, and the combined global sales of all mAbs on the market 
were  estimated  at  $44.6  billion,  which  was  approximately  5%  of  the  total  global  
pharmaceutical sales (BCC-Research, 2012). Furthermore, this figure is expected to rise to 
$58 billion by 2016, which means that mAbs represent a significant source of revenue for the 
pharmaceutical industry. Currently, 10 out of the 32 mAb drug products that have received a 
marketing authorization are produced by freeze drying, meaning that it remains a relevant 
production method for therapeutic antibodies. Since freeze-dried protein drug products are 
partially or completely amorphous systems, in order to understand them, one must first 
understand the nature of the amorphous state. 
 
 
2.2 Amorphous state and water sorption 
 
2.2.1 Structure and different transitions in amorphous state 
The atoms or molecules that form solid matter are often depicted as being arranged in 
crystalline form. Despite exhibiting some irregularities (defects), the crystalline form is a 
highly ordered state (Fig. 3) and its physicochemical properties are very uniform throughout 
the crystal lattice. A transition from the crystalline phase to another, such as to liquid, 
manifests as a stepwise change in enthalpy (H), entropy (S) and free volume (Vf),  and  it  
involves a fixed latent heat that is consumed during the phase change without a change in 
temperature (as shown in Fig. 4). Such a transition is known as a 1st order phase transition. 
However, not all materials that appear solid by nature are crystalline. Liquids that are cooled 
below their melting temperature (Tm) do not necessarily crystallize under experimental time 
scale,  but  as  shown in Figure 4,  they may form supercooled liquids  instead.  Cooling such a  
liquid further increases its viscosity, and at some point the movement of individual molecules 
becomes so slow that they no longer have time to rearrange as their most energetically 
favorable  liquid conformation (Ediger  et  al.,  1996).  This  causes  H,  S  and Vf to deviate from 
the liquidus curve and the supercooled liquid eventually becomes practically immobile, as 
molecules can no longer move past each other under experimental time scale (i.e. their 
translational molecular mobility becomes very limited, but significant rotational and 





the glass transition (Tg, -transition), and while the glassy material below Tg may appear 
totally solid, its molecular lattice exhibits only short range order (as seen in Fig. 3). 
Therefore, the glassy state is differentiated from both the crystalline and liquid states, since 
on molecular level its structure is similar to a highly viscous liquid, but its specific heat 
capacity and thermal expansion coefficient are closer to crystalline than liquid form 




Figure 3. A schematic representation of crystalline (left) and amorphous (right) states, with 






Figure 4. Changes in H, S and Vf as functions of temperature for a material that can exist in 
either crystalline or amorphous form under Tg. Glass 1 is formed as a result of faster cooling 
than glass 2. Adapted from Ediger et al. (1996). 
 
As can be seen from Figure 4, cooling a liquid at different rates will produce glasses 
with differing Tgs and physical properties, such as H, S and Vf (Moynihan et al., 1974). This is 
because the cooling rate affects how much time individual molecules have to arrange, or 
“relax”, towards the equilibrium conformation before they are apparently immobilized at Tg. 
As Tg is a kinetically controlled phenomenon which occurs over a temperature range without 





2.2.2 Molecular mobility of amorphous compounds 
Even though the glassy state is physically more stable than the supercooled state, all 
glasses will relax towards the equilibrium enthalpy of the corresponding crystalline state 
when aged (annealed) under Tg (Ediger et al., 1996). Therefore, despite their different 
production methods, glass 1 in Figure 4 can theoretically be converted into glass 2 by 
annealing it for a certain amount of time. The relaxation rate is dependent on the structure of 
the glass, as well as the annealing temperature, and relaxation leads to a decrease in H, S and 
Vf as individual molecules and ordered molecule clusters reach a state of lower 
conformational energy. The structural relaxation time ( ), i.e. the time after which the 
intermolecular structure of a liquid/glass no longer bears resemblance to the structure at an 
earlier time point, is approximately 100 seconds at Tg and it increases rapidly when 
temperature is decreased. When relaxation proceeds, molecular mobility is simultaneously 
reduced  due  to  a  decrease  in  excess  H,  S  and  Vf in relation to the equilibrium (crystalline) 
state. Both the time and temperature dependence of relaxation rate may be modeled for 
example by using the Adam-Gibbs-Vogel equation (Adam and Gibbs, 1965), where the 
deviation of the glass structure from equilibrium is depicted by using the concept of fictive 










exp    (1) 
 
In Equation (1), 0 is the pre-exponential factor (usually taken as 10-14 s), D is the so-
called strength parameter and T0 is the temperature where relaxation times approach 
infinity. D describes the deviation of a material's initial relaxation rate from Arrhenius 
temperature dependence, large values meaning "strong" materials that follow Arrhenius 
behavior, and small values "fragile", non-Arrhenius behavior following materials. 
It should be noted, however, that there are several different ways to characterize 
molecular mobility. In addition to translational (global) mobility, molecules also possess 
rotational and vibrational (local) mobility and distinguishing between these may sometimes 
be difficult, especially when studying their combined effects on protein stability (see chapter 
2.3.3). Still, all molecular mobility seems to affect the crystallization rate from amorphous 
state. Upon crystallization, intra- and intermolecular hydrogen bond networks of molecules 
form repeating motifs based on the most stable structure available and the overall energy of 
the system (Etter, 1990). Ordering of the molecules requires some degree of mobility, 
because in amorphous state the molecules are randomly oriented at “long” range. Maximum 
crystallization rate is normally observed between Tg and  Tm, where rapid global mobility 
facilitates the reorientation of molecules (Bhugra  and Pikal, 2008). On the other hand, it has 
been previously shown that crystallization may also be initiated at very low temperatures 
relative to Tg, in some cases even at Tg - 175°C (Okamoto and Oguni, 1996), where global 
molecular mobility should be extremely limited. This may mean that local mobility alone, 
such as the rotation of hydrogen bond forming moieties, may be sufficient to allow the 






2.2.3 Water sorption and its effect on molecular mobility 
In addition to the temperature effect described in the previous chapter, the molecular 
mobility  of  a  glass  can  also  be  altered  by  mixing  additional  components  into  it.  This  is  
because mixing equal amounts of two miscible compounds will form a glass with a single 
intermediate Tg between the glass transition temperatures of the individual components 
(Hancock   and  Zografi,  1994).  Tg lowering compounds are often referred to as plasticizers, 
and their addition increases molecular rotation and movement in the amorphous mixture. If 
a solute and a solvent, here a pure compound glass and a plasticizer, with different Tgs are 
mixed  without  a  change  in  the  overall  volume  of  the  system,  Tg of the mixture will change 
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where Tg1 and Tg2 are the glass transition temperatures of the solute and solvent and w1 




    
(3) 
 
where 1 and  2 are the densities of the solute and solvent and 1 and  2 their 
increments of thermal expansion coefficient at glass transition, respectively. The material 
coefficient K gives the extent of Tg depression as a function of solvent content, with a higher 
value indicating a more steep change. Equation (2), known as the Gordon-Taylor equation 
(GT), was originally formulated to describe the glass transition temperature changes in 
polymer blends (Gordon  and Taylor, 1952). However, it has since been successfully 
employed for modeling different kinds of amorphous mixtures as such, or with small 
modifications (Hancock  and Zografi,  1994; Rodriguez Furlan et al.,  2011). The GT model is 
highly useful in the prediction of Tg changes in two-component mixtures as a function mixing 
ratio, but its results are dependent on sample pretreatment and measurement parameters 
(Frank, 2007). Therefore, care must be employed when comparing values acquired from 
different literature sources.  
One of the most common plasticizers in amorphous hydrophilic pharmaceuticals is 
water, which has a Tg of approximately -135°C (Haque  and Roos, 2003). With such a low Tg, 
it is evident from Equation (2) that even a small increase in water content will significantly 
reduce the overall glass transition temperature of an amorphous mixture. When evaluating 
the effect of water as a plasticizer, it should be noted that the plasticizing effect of water may 
depend on how it interacts with the amorphous phase. Water in crystalline state, such as in 
ice or hydrate lattice, may be restricted from interacting freely with other components of the 
system. On the other hand, water that is mixed within the glass has the possibility of affecting 
its molecular mobility more. At a given temperature, the mobile water content of a system at 












   
(4) 
 
where pw equals the equilibrium partial vapor pressure of water in a system and pw0 the 
equilibrium partial vapor pressure of pure liquid water, both in a given temperature (hence 
the subscript T). It should be stressed that aw is not an absolute measure of water content, 
whether it is mixed within the amorphous phase or not, and it only describes the fugacity 
(escaping tendency) of water from the overall system. Changes in aw can therefore be due to 
an alteration either in total water content (e.g. sorption/desorption), in water mobility (e.g. 
crystallization/melting), in sample hydrophilicity/-phobicity or in the porosity or dimensions 
of the overall sample. 
 Water sorption characteristics of a system under isothermal conditions can be 
modeled, for example, by using the Brunauer-Emmett-Teller (BET) equation, which predicts 
the sorption isotherms well for aw between 0 - 0.55 (Brunauer et al., 1938). The BET model 
was originally created to model the adsorption of nonpolar gases on nonpolar surfaces, but it 
has since been also employed to model the water sorption of different amorphous saccharides 
(Zhang  and Zografi, 2000). The model can be used to calculate, for example, the amount of 
water necessary to generate a monolayer of water molecules on the solid surface, which gives 
an estimate of available water binding sites on that surface. In its linearized form, the 














where m is the water content in grams per every 100 g of solids and m0 is the amount of 
water in one monolayer in the same units. C is the heat constant of surface sorption, which 
has been hypothesized to be affected by the effect of water plasticization on the free energy of 
the  amorphous  system,  as  well  as  by  the  chemical  affinity  of  water  on  solids  (Zhang   and  
Zografi, 2000). C-values between 2–50 are often observed in case of amorphous solids, 
whereas lower (< 2) are more common for crystalline materials (Labuza and Altunakar, 
2007). 
Water plasticization affects the molecular mobility of amorphous systems, which in 
turn is closely linked to protein stability in dry formulations. Therefore, studying how water 
uptake affects an amorphous formulation is of utmost importance when deciding what kind 
of processing and storage conditions are acceptable for that particular product. 
 
 
2.3 Protein instability 
 
Protein instability is a concept that can include both covalent bond breaking or formation in 
proteins that leads to the formation of new chemical entities (chemical instability), as well as 
non-covalent changes that result in alterations in secondary, tertiary and/or quaternary 
protein structures (physical instability) (Manning et al., 1989). This is, of course, not always a 
clear division, and distinguishing between the two may be difficult at times. Protein stability 
in different types of products is governed by a large number of factors, and introducing all of 





important ones regarding aqueous solutions, as well as frozen and dried systems are 
discussed below. 
 
2.3.1 Factors affecting protein stability in aqueous solutions 
Proteins are often thermolabile, and their three dimensional structure tends to become 
unfolded (denaturated) above certain temperatures. In the simplest two-state model this can 
be described as (Pace, 1975): 
 
   (6) 
 
where N denotes the native and U the unfolded (or denaturated) state. The transition 
from native to unfolded occurs because an increase in temperature weakens the hydrophobic 
bonding, disrupts intramolecular ion pairs and strengthens the hydrophobic surface 
interactions, all of which affect the three dimensional structure of proteins (Jaenicke, 1991). 
When heated at a constant rate, the temperature where approximately 50% of proteins are 
unfolded is known as the “melting” or denaturation temperature (Td),  and  the  value  is  
sometimes used to characterize the thermostability of a given protein (Wang, 1999). 
However, it is possible for a protein to have two or more denaturation temperatures 
depending on the experimental conditions and the analytical methods used. For example, 
several denaturation temperatures may be observed if the protein forms stable unfolded 
intermediates upon heating (Kosa et al., 1998) or if it contains several domains, each of which 
unfold individually (Remmele et al., 1998). 
In addition, proteins can also be denaturated at low temperatures. This “cold 
denaturation” is thought to be caused by the hydration of non-polar moieties, which leads to 
somewhat similar secondary structure alterations as high temperature denaturation 
(Jaenicke, 1990). Despite the fact that proteins are subjected to low temperatures during 
freeze drying, cold denaturation does not appear to significantly contribute to protein 
instability during processing (Bhatnagar et al., 2007). In fact, some proteins may maintain 
their biological activity for extremely long periods of time when they are maintained in 
supercooled aqueous solutions, for example between -12 and -20ºC (Hatley et al., 1987). 
As protein structures are largely dependent on the balance between their hydrophobic 
and -philic moieties, it is no wonder that pH and ionic strength significantly affect their 
conformational stability (Goto and Fink, 1989). A change in pH of the surroundings can 
ionize a number of protein subgroups, and if these ionizing groups are located in the interior 
of folded proteins, they tend to destabilize protein conformations due to electrostatic 
repulsions (Yutani et al., 1987). The effect of ionic strength is dependent on pH (Goto and 
Fink, 1989), and the interplay between the two is often difficult to predict. Solution pH may 
also affect the rate at which chemical reactions leading to protein degradation progress, such 
as in the case of Maillard reaction in the presence of reducing compounds (see chapter 2.5.1) 
(Martins et al., 2001). 
Mechanical stress may lead to structural perturbations in proteins. For example, 
antibodies appear especially susceptible to three dimensional structure alterations (Mahler et 
al., 2005), but the effects of different kinds of mechanical stresses on antibody stability, such 
as those caused by shaking or stirring, may vary (Kiese et al., 2008). The source of the 
mechanical stress factor has been attributed to the formation of an increased air/water 
interface area as bubbles are formed (Eppler et al., 2010). Shearing during processing might 
also denature proteins, but it has been calculated that the force exerted on proteins at 





2009). Shaking-induced aggregation has been shown to be aggravated in the presence of 
silicon oil (Thirumangalathu et al., 2009), which is sometimes used in primary packaging as 
lubricant. The oil may also be transferred into the solution during processing, or during 
shipping when it comes into contact with the stopper. 
If an aqueous solution contains other dissolved compounds besides the protein, these 
compounds may have an effect on protein stability. This is because in an aqueous protein 
solution that does not contain any additional solutes all the available surface sites of the 
protein are occupied by water molecules. However, when additional solutes (s) are present, 
some of the water molecules (H2O) on protein surface sites (P) tend to be replaced by these 




where Kex represents the exchange coefficient:  
 
  (8) 
 
where KS and  KH2O are the solute and water binding constants, respectively. Protein 
conformation has an effect on KS, and in some cases the solute interacts more strongly with 
the protein after protein unfolding has taken place (Timasheff, 1992). In such a case, the 
activation energy of protein denaturation is lowered by the addition of the solute, which 
shifts the overall balance of the reaction to the right in the two-state protein folding model 
depicted by Eq. (6). Examples of solutes that are preferentially bound to protein surface sites 
over water include urea and guanidine hydrochloride, but their effect on the denaturation 
activation energy seems to vary between different proteins (Pace, 1975). This is most likely 
due to differences in protein structures. 
However, solutes may also stabilize proteins. If Kex <  1,  the  solute  in  question  is  
preferentially excluded from the surface sites, which leads to the preferential hydration (i.e. 
increased water interaction) of the overall protein surface. As a result, the chemical potential 
of the solution is increased, as the solute molecules are less likely to be located near the 
protein surface than farther away from it (Lee and Timasheff, 1981; Timasheff, 1992). Since 
protein unfolding is generally accompanied by an increase in surface area (Lee and 
Timasheff, 1981), denaturation is thermodynamically less favorable in the presence of 
preferentially excluded solutes, because it would lead to a further increase in the chemical 
potential of the solution. Examples of such solutes include disaccharides such as sucrose, as 
well as polyalcohols such as sorbitol (Timasheff, 1992). If a solution contains both 
preferentially bound and excluded compounds, their concentration differences and 
tendencies to interact with the protein define the overall effect on denaturation activation 
energy. It should be noted that preferential exclusion only affects solutions. If the solvent is 
removed, the concentration gradient disappears and preferential exclusion can no longer be 
used to describe protein stability (Allison et al., 1996; Carpenter and Crowe, 1989). 
 
2.3.2 Factors affecting protein stability in freezing aqueous solutions 
Cold denaturation (see previous chapter) must always be separated from freezing-
induced protein stress. Firstly, freezing creates new liquid/solid interfaces into the solution, 
forming an electric potential difference gradient in the vicinity of the interface (Workman 





be direct protein adsorption to ice, which provides the thermodynamic driving force for 
unfolding by increasing the entropy of the system (Bhatnagar et al., 2007). This kind of 
adsorption can also take place at the water/container interface, but because of the small size 
of ice crystals, their surface area is considerably larger than that of the container in a freezing 
system. Still, even the ice surface area is finite, and it can be saturated with proteins or other 
compounds. The extent of surface-induced unfolding seems to be protein-dependent, but 
protein adsorption characteristics vary between different surfaces (Vermeer et al., 1998), 
such as glass or rubber. Freezing also reduces the amount of liquid water in the system, 
which in turn increases the concentration of all solutes. This can lead to an increase or 
decrease in protein stability, depending on the solute in question. In some cases, higher 
protein concentration may decrease the extent of unfolding during freezing (Allison et al., 
1996;  Liu  et  al.,  2005).  One  explanation  for  this  is  that  if  the  protein  concentration  of  the  
aqueous solution is relatively high before freeze concentration, freezing may increase it to a 
point where the proteins inhibit each other’s molecular movement through steric hindrance. 
Another explanation is that proteins are unfolded at the ice/water interface and a high 
enough protein concentration can saturate that interface, which protects the protein 
molecules that are not in contact with the ice/water layer. 
If the freezing solution contains buffers that have a tendency to crystallize, freeze-
concentration may lead to pH shifts that can be harmful for proteins (see chapter 2.3.1). 
Similarly, compounds that increase protein stability in aqueous solutions through 
preferential exclusion may crystallize during freeze-concentration, revoking their protective 
effect and forming solid/liquid interfaces which may further destabilize proteins (Piedmonte 
et al., 2007). Finally, the freeze-concentration of the protein itself may result in a high 
concentration phase, where the protein solubility limit is exceeded, or cause the attractive 
protein surface forces to exceed the repulsive ones, leading to higher rate of chemical 
reactions and/or aggregation (Shire et al., 2004). 
 
2.3.3 Factors affecting protein stability in amorphous state 
When aqueous protein formulations are dried, the water surrounding proteins is 
removed either partly or completely. Water acts as a stabilizing component for proteins, since 
it keeps individual polypeptide chains apart and helps to conserve their three dimensional 
structure. The amount of water required for full hydration has been approximated to be less 
than 0.25 g per one gram of protein (Jaenicke, 1991). Removing a part of the water 
surrounding the proteins may cause some ionized moieties to lose their charge, which 
decreases the activation energy of hydrophobic interactions between neighboring proteins 
and can lead to conformational alterations. Such harmful dehydration effects may be 
countered, or made reversible, if the initial formulation contains compounds that are able to 
form hydrogen bonds with protein surfaces (Carpenter and Crowe, 1989). These compounds 
may partly replace water around the protein, and mimic the effects of the hydration shell that 
is necessary for upholding the three dimensional structure close to native. Such action seems 
to result in an improved retention of the biological activity of proteins (Prestrelski et al., 
1993a), and molecules that contain many hydrogen bond forming moieties, such as 
carbohydrates, tend to be suitable for this purpose. On the other hand, larger polymeric 
molecules might not be able to form a sufficient amount of hydrogen bonds with the protein 
due to steric hindrance, which may make some of them less effective hydrogen bond 
replacing compounds (Tanaka et al., 1991). It also seems that even the most stabilizing 
compounds cannot completely replace all water of the hydration shell. Therefore, protein 





For example, a dried antibody product with an intermediate water content (  3%-w/w) has 
been shown be more stable during storage than those containing less or more water than this 
(Chang et al., 2005). 
If a solution contains solutes (besides the protein-structured API) that do not crystallize 
from supercooled solutions at subzero temperatures under experimental time scale, these 
may form a glassy matrix during cooling and freeze-concentration that envelops proteins. 
Such compounds can therefore be used to encase proteins within a viscous matrix, which 
limits the molecular mobility of the protein, and may slow down the interconversion between 
conformational states (Hagen et al., 1995). The role of the viscous matrix in protein 
stabilization, however, is still not completely understood. The molecular mobility of an 
amorphous matrix at temperatures under Tg may be divided into translational (global) and 
vibrational (local) mobility, as explained in chapter 2.2.2, and their individual and combined 
effects on protein stability are yet to be elucidated. However, it has been hypothesized that 
the effect of global molecular mobility on the storage stability of dried amorphous protein 
products may be sometimes limited (Yoshioka and Aso, 2005), whereas local mobility may 
play a more significant role (Chang et al., 2005; Yoshioka et al., 2007). The plasticizing effect 
of residual water content (described above) must also be taken into account when 
determining the molecular mobility of an amorphous phase, as explained in chapter 2.2.3. 
Naturally, the crystallization of a protective glass forming compound will exclude 
proteins from its vicinity and decrease its protective efficacy, as proteins cannot be included 
within the ordered crystal lattice of the protective compound (Izutsu et al., 1993). Similarly, 
crystallization reduces the amount of heteromolecular hydrogen bonds that the protective 
compound may form, which makes it less effective in replacing water as a hydrogen bond 
former with the hydrophilic protein surface (Carpenter and Crowe, 1989).  
 
2.3.4 Protein aggregation and fragmentation  
Chemical and physical protein instability may lead to a number of different outcomes, 
but one of the most distinguishable ones is certainly aggregation. It is a relatively common 
response to most stress factors, since any kind of transition in protein structure that leads to 
a change in the attractive and repulsive forces between protein molecules, including the 
formation of intermolecular covalent bonds, may possibly lead to aggregation (Wang, 1999). 
However, due to the complexity of protein structures, two aggregates are never completely 
alike. Protein aggregate classification systems based on their size, reversibility of formation, 
conformation, possible chemical modification and morphology have been suggested by 
several  authors,  such  as  Mahler  et  al.  (2009)  and  Narhi  et  al.  (2012),  as  shown  in  Table  1.  
Classifying the aggregate profile found from pharmaceutical products is important, because 
differences in their size, chemical composition and surface properties may cause a change in 
their biological response (see chapter 2.3.5). There are a number of different aggregation 
pathways that proteins may undertake, some of which are shown in Figure 5. It should be 
noted that this clearly differs from the simple two-state model described in Eq. (6), where no 
intermediate formation is considered due to sake of simplicity. Proteins can aggregate 
directly from the native state, as shown by pathway 2, either by forming potentially reversible 
electrostatic and/or hydrophobic interactions (2a) or through practically irreversible covalent 
crosslinking (2b) in Figure 5. Partial structural deformation (i.e. intermediate formation) 
prior to aggregation also appears to be common, whereas aggregation through completely 
denatured state may be more rare, which is represented by the gray arrows. Disulfide bridge 
formation/exchange plays an important role in covalent crosslinking (Carba et al., 2008), 





pathway 2b or indirectly through pathway 3. However, other chemical reactions such as the 
Maillard reaction can also have a similar result as disulfide bridging (Wang et al., 2010). 
Even though protein aggregates may initially be soluble, they may eventually precipitate as 
amorphous or ordered structures, once a certain size or solubility limit is exceeded. 
 
Table 1. Properties that can be used to describe and divide aggregates into different 





size small oligomers, large oligomers ( 10-ers), soluble particles 
 
with Ø = 20 nm – 1 µm,  insoluble particles with Ø = 1 - 
25µm, large visible particles 
reversibility Reversible, irreversible, dissociable (under given conditions) 
conformation  Predominantly native, predominantly non-native 
chemical modification  Cross-linked, intramolecular modification, oxidation etc. 






Figure 5. A general scheme representing possible protein aggregation pathways. Pathway 1 
represents aggregation through intermediate unfolding, pathway 2 through protein self-
association and pathway 3 through chemical linkage formation. Subscripts a and b stand for 
reversible and irreversible aggregation, respectively. Black arrows represent primary (more 
common)  and  gray  arrows  secondary  (less  common)  pathways.  Adapted  from  Wang  et  al.  
(2010). 
 
In addition to aggregation, proteins may also undergo fragmentation to form units that 
are smaller than one monomer in size. This is relative common in antibodies such as 
immunoglobulin G (IgG), where the protein monomer is actually a homodimer of two heavy 
chain/light chain pairs, and these can relatively easily be separated into smaller subunit, for 
example by extreme pH conditions (Usami et al., 1996), high temperatures (Alexander and 
Hughes, 1995) or freeze-thawing (Paborji et al., 1994). This will reduce the active monomer 
content, possibly decreasing the efficacy of the product and causing structural alterations 






2.3.5 Product-related immunogenicity 
Non-native proteins may cause an immune response when entering the blood stream. 
When this happens, either with or without being activated by helper T-lymphocytes, B-
lymphocytes begin producing antibodies that bind specifically to a certain epitope of the non-
native protein (Rosenberg, 2006). It would appear that the epitopes that activate B-
lymphocytes may be expressed not only in the linear amino acid sequence, but in the three-
dimensional protein conformation as well (Ito et al., 2003). This would suggest that 
alterations even in the conformation of fully human proteins might turn them immunogenic. 
Also, the formation of protein aggregates may create three-dimensional structures that are 
not expressed in native-form proteins, which has led to the hypothesis that such aggregates 
might be immunogenic. 
There are most likely several factors that determine the prevalence and nature of 
immune response in patients caused by a biopharmaceutical drug product. Based on non-
clinical data, it has been suggested that products with higher aggregate content might trigger 
a stronger immune response than those with lower content (Gamble, 1966). On the other 
hand, in a more recent non-clinical study it has been suggested that the structure and 
formation method of aggregates affects their immunogenicity more than their quantity or 
size (Filipe et al., 2012). It has been hypothesized that differences in aggregation methods 
might affect their surface structure as a result of monomer unfolding, reordering and 
chemical modification, and certain structural features such as repetitive epitope ordering 
might induce a stronger immune responses than others (Filipe et al., 2010b). In extreme 
cases, the immune response caused by a drug product can lead to life-threatening conditions 
such as anaphylactic shock, but immunogenicity might also lead to reduced therapeutic 
efficacy in long term administration (Rosenberg, 2006). This is because sometimes the 
immune system creates anti-drug antibodies only against the unfolded proteins, but on some 
occasions it may adapt to activate against the native form as well (Vazquez-Rey and Lang, 
2011). The resulting reaction may therefore inactivate a portion of the dose and reduce the 
efficacy of the drug. Whether this is commonly clinically relevant, however, is unclear. 
It should be noted that direct clinical evidence identifying aggregates as a major 
contributing factor in the immunogenicity of biopharmaceutical products is still missing 
(Singh  et  al.,  2010).  Furthermore,  it  is  often  difficult  to  find  reliable  causes  for  
immunogenicity differences between protein drug products, as there are several factors 
contributing to this. For example, there may be significant differences in the immunogenicity 
of drug products containing structurally similar proteins. In one such case, the percentage of 
patients developing neutralizing antibodies against the protein-structured API was 13% for 
an interferon (INF)  -1a product (Avonex®,  Biogen IdeC Inc.,  Weston, MA, USA) and 43% 
for an INF -1b product (Betaferon®, Bayer HealthCare Pharmaceuticals, Berlin, Germany) 
(Sominanda  et  al.,  2007).  Comparing  the  two  products  is  made  difficult  by  the  fact  that  
besides containing APIs with different protein structures, Avonex® is an aqueous solution 
that is administered intramuscularly, whereas Betaferon® is freeze-dried and administered 
subcutaneously. It is also noteworthy that in the study of Sominanda et al. (2007) Avonex® 
and Betaferon® were administered to different patients. This is relevant, because the immune 
systems of different patients may react differently to a given product (Jahn and Schneider, 
2009), meaning that there may be differences in the apparent immunogenicity of a drug 
product depending on the patient group to which it is being administered. 
Based on the possible effect of protein aggregation on product immunogenicity, the 
measurement of product aggregation profiles is currently under intense discussion in the 





aggregate content quantification, such as the Ph.Eur chapter 2.9.19 and the USP chapter 
<788>, only give maximum allowed particle content limits for particles larger than 10 µm in 
size. Consequently, they have been criticized for not being fully descriptive of the quality of 
biotechnological products on the basis that smaller aggregates than this may still be 
immunogenic (Carpenter et al., 2009). Furthermore, other aggregate properties besides size 
are not controlled. However, if the effect of protein aggregation on immune response is to be 
estimated, accurate qualitative and quantitative aggregate analysis methods are required. 
This represents a serious problem in the current analytical technologies, because especially in 
the case of submicron aggregates, factors such as sample pre-treatment and measurement 
method heavily affect the results (Singh et al., 2010). The lack of universally accepted 
analysis methods that could differentiate between protein aggregates, silicon oil droplets and 
air bubbles may therefore make it difficult to set regulatory limits for submicron particles 
present in drug products. Therefore, International Conference on Harmonization (ICH) 
guideline Q6B on the test procedures and acceptance criteria for biotechnological products 
states only that these products should be fully characterized to ensure their safety and 
efficacy  (ICH,  1999).  Resolving  a  suitable  methodology  for  this  must  be  done  by  the  
manufacturer on a case-by-case basis (Jahn and Schneider, 2009). 
 
 
2.4 Freeze drying 
 
Freeze drying, or lyophilization, is a common method for drying heat sensitive 
materials, such as biological samples and proteins. It consists of dissolving the compound(s) 
to be freeze dried in a solvent, freezing the solution and then removing the crystalline solvent 
through sublimation and evaporating the non-crystalline solvent. From here on only the 
freeze drying of aqueous solutions is considered, even though it is possible to use other 
solvents that are liquids in room temperature for compounds that do not dissolve in water. 
Freeze drying is commonly divided into three stages, freezing, primary drying and secondary 
drying, and the shift from one stage to the next can usually be identified as the point when 
the main type of phase transition occurring in water changes (e.g. from crystallization to 
sublimation). An illustration of an imaginary conventional freeze drying cycle is shown in 
Figure 6. It should be noted, however, that temperatures and drying times tend to vary 
significantly between cycles.  
Although there are several models available on the market, industrial scale freeze 
dryers always tend to contain temperature-controllable shelves where the product vials are 
kept, a condenser and a vacuum pump. The shelves can be used to cool the solutions to be 
freeze dried, resulting in ice crystal formation, and to affect product temperature and water 
removal rate during all process stages. The condenser is needed to remove sublimed water 
from the air by deposition, and the vacuum pump is necessary to control chamber pressure 
during primary and secondary drying. The three stages that make up the freeze drying 







Figure 6. A depiction of a fictional freeze drying cycle, where the effects of shelf temperature 
and chamber pressure on sample temperature during drying are shown during different 
stages of drying. 
 
2.4.1 Freezing 
To begin a freeze drying process, the temperature of an aqueous solution containing the 
API and excipients (solutes) must be lowered in order to turn the majority of liquid water 
(solvent) to solid ice crystals. The part of the freeze drying process leading to the formation of 
this solid intermediary product is generally referred to as the freezing phase, and the phase 
transitions occurring during it are depicted in Figure 7. Upon cooling, the aqueous solution 
does not normally freeze at the equilibrium freezing temperature of the solution (denoted by 
[I] in Fig. 7), as crystallization is a stochastic phenomenon (Franks, 2007). The extent of how 
much the temperature of the solution decreases below its equilibrium freezing temperature 
before the appearance of ice crystals is known as the degree of supercooling. When ice 
nucleation does occur, the extent of supercooling determines the growth rate of ice crystals. 
This is because the driving force for crystallization is higher when the solution is more 
supercooled, and a higher degree of supercooling will therefore result in faster nucleation 
rate and smaller average crystal size (Kasper and Friess, 2011). As higher extents of 
supercooling are usually achieved by using slower cooling rates, very fast cooling may 








Figure 7. State diagram of a system containing water (W) and solute (S).The explanations of 
markings [I] through [III] and [1] through [2] are given in text. The major physical states 
present and phase transitions occurring under different conditions are marked with either 
black  or  gray,  depending  on  whether  the  predominant  behavior  of  the  solute  under  
experimental time scale in solutions at that temperature is crystallization or vitrification, 
respectively. Adapted with changes from Liu et al. (2005). 
 
Ice crystal formation increases the temperature of the dispersion due to the latent heat 
release of crystallization, and the removal of water from the solution increases the 
concentration of solutes (marked with [1] in Fig. 7). When the dispersion freezes further, the 
concentration of solutes follows the equilibrium freezing curve (marked with [I]) until the 
equilibrium solubility curve (marked with [II]) is met. At this temperature (known as the 
eutectic temperature, Teu) the concentration of readily crystallizing solutes becomes high 
enough to allow crystallization, but like in the case of ice formation, this phase transition 
tends to occur at a temperature below Teu. The readiness of supersaturated solutes to 
crystallize is dependent on the complexity of their crystal structure, and in the case of 
compounds such as disaccharides this structure is so complex that they do not normally 
crystallize from supersaturated solutions under experimental time scale (Kasper and Friess, 
2011). In such cases cooling the solution will cause further freeze concentration along the 
equilibrium concentration curve (marked with [III] in Fig. 7). When cooled to a sufficiently 
low temperature, the viscosity of the solution will eventually exceed the point where the 
translational mobility of solute molecules becomes negligible. This point is known as the 
glass transition temperature of the maximally freeze-concentrated amorphous phase (Tg’), 
and due to the drastic reduction in molecular mobility, ice crystal growth no longer takes 





the total water present in the original solution into ice, the solute concentration of the 
maximally freeze-concentrated amorphous phase (Cg’) tends to be independent on the initial 
solute concentration (Franks, 1998), except in very dilute solutions. 
After the solution has been frozen below Tg’, no significant changes in ice crystal size or 
solute concentration are expected to occur under experimental time scale. However, if the 
solution has been cooled very quickly (e.g. by using liquid nitrogen quenching), solute 
concentration may not have increased along the equilibrium concentration curve (marked 
with [III] in Fig. 7), as freeze-concentration takes time. Therefore, the solute concentration 
will be below Cg’. This means that the Tg of the solute phase is now lower than Tg’ due to its 
higher water content, as dictated by the Gordon-Taylor equation (Eq. (2) in chapter 2.2.3), 
and this may pose problems during primary drying (see next chapter). In such cases the 
solution temperature may be increased above its glass transition temperature to allow further 
freeze-concentration to take place (marked with [2] in Fig. 7). However, care must be taken 
not to exceed the onset melting temperature of ice (Tm’), above which the ice starts turn into 
liquid water, causing a decrease in solute concentration and the amorphous phase.  
This heat treatment method, known as annealing, can also be used to affect the ice 
crystal size after freezing has already taken place. Holding the temperature between Tg’ and 
Tm’ increases molecular mobility, allowing the interchange of molecules between solid ice and 
liquid water phases to take place. Ice crystals with relatively small radius of curvature tend to 
shrink, eventually disappearing completely, while large crystals grow (Searles et al., 2001). As 
a result, the average ice crystal size increases and size distribution decreases. This 
phenomenon is known as Ostwald ripening, and as its result, annealing can be used to 
increase and homogenize the average ice crystal size of frozen samples. It may also decrease 
primary drying time, as sublimation of the large ice crystals forms large pores which offer less 
resistance to water removal than small pores. Furthermore, narrowing the ice crystal size 
distribution may produce less variation between vials when a large number of samples are 
freeze dried simultaneously. Finally, annealing may be used to complete the crystallization of 
unstable excipients such as mannitol, when they are meant to crystallize and serve as bulk 
formers in the lyophilizate (i.e. the end product of freeze drying process). 
Varying the cooling, and subsequently the freezing rate may have an effect on protein 
stability. Freezing solutions quickly by cryogen quenching (e.g. using liquid nitrogen) tends 
to lead to the formation of a large ice surface area due to the formation of many small ice 
crystals, and this surface area can act as an adsorption site for proteins such as bovine IgG 
(Sarciaux et al., 1999), as explained in chapter 2.3.2. The relationship between freezing rate 
and the extent of protein stress may be depend on the protein that is being frozen, however, 
as freezing lactate dehydrogenase by liquid nitrogen quenching has been shown to cause less 
protein activity loss than freezing it slowly on the shelves of a freeze drier (Nema and Avis, 
1993). A reason for this may be that since fast freezing decreases the extent of freeze 
concentration of the solute phase, it may be less harmful to proteins which are susceptible to 
structural alterations in highly concentrated solutions. 
 
2.4.2 Primary drying 
After freezing the solution, ice is removed from the product by sublimation, i.e. by 
transforming solid water to vapor, which is carried out in a stage commonly referred to as 
primary drying. Since the crystalline phase tends to contain most of the total water in the 
sample (the rest being in unfrozen state in the freeze-concentrated amorphous phase), 
primary drying is usually the most time-consuming part of the freeze drying process, and 





(Chang and Fischer, 1995; Chatterjee et al., 2005; De Beer et al., 2007). Sublimation can be 
initiated by decreasing drying chamber pressure and increasing shelf temperature in such a 
way that the triple point of water is not exceeded. Sublimation of ice takes large amounts of 
energy (  2.8 kJ/g), meaning that the subliming ice front cools down significantly if 
additional heat is not supplied. Heat can be transferred from the surroundings through three 
mechanisms, radiation, conduction and convection, of which convection has the greatest 
effect on product temperature during primary drying (Franks, 2007). Still, even though 
chamber pressure affects the rate of sublimation, it is not the driving force. This force is 
provided by the vapor pressure difference between the sublimating water front, and the 
condenser surface where water deposits. Therefore, condenser temperature should normally 
be a low as possible, since increasing the temperature difference between sublimation and 
deposition fronts will improve the rate of sublimation. 
Carrying  out  primary  drying  so  that  the  amorphous  phase  remains  in  highly  viscous  
state will result in the formation of a porous lyophilizate structure, as shown in Figure 8, 
where the pores are formed after ice crystals sublime. Normally, product temperature is kept 
close  to  or  at  Tg’  during  primary  drying  (Tang  and  Pikal,  2004).  This  is  because  a  higher  
product temperature allows the material to be dried faster, reducing production costs. On the 
other hand, exceeding Tg’ may bring the temperature close to the collapse temperature (Tc). 
This temperature represents the point where the viscosity of the amorphous phase becomes 
sufficiently low to allow it to flow significantly under experimental time scale. Tc may in some 
cases be observed as close as 2°C above Tg’, and exceeding it will cause the pores to start 
closing and the overall dimensions of the lyophilizate to decrease (so-called macrocollapse, or 
simply collapse). Macrocollapse may decrease drying rate during primary and secondary 
drying, since the porous structure can improve drying (especially when using large vial fill 
volumes), and collapse will also make the product visually unappealing. Exceeding Tg’ during 
primary drying has also been suggested to have a negative effect on the stability of protein-
structured pharmaceuticals, but this theory has been called into question in several recent 
studies (see below).  
 
 
Figure 8. A scanning electron microscope image of freeze-dried melibiose (magnified x350), 





The interplay between shelf temperature and chamber pressure is illustrated in Figure 
9, which depicts an imaginary system undergoing primary drying. If the system is being dried 
on shelves that are being kept at temperature X, under the chamber pressure of 45 A.U. 
(arbitrary units), the heat transfer balance keeps product temperature close to Tg’ (point A). 
Reducing the chamber pressure to 22.5 A.U. will cool the sample by over 5 K, but it will also 
reduce sublimation rate due to lower product temperature, as heat convection slows down 
(point B). Increasing the chamber pressure to 60 A.U. will increase sample temperature 
almost  2.5  K  above  Tg’ and improve sublimation rate, as heat convection becomes more 
effective (point C). However, this increase in temperature may bring product temperature 
close to Tc and result in product collapse. In a conventional freeze drying cycle shelf 
temperature and chamber pressure are normally optimized to maximize sublimation rate, 




Figure 9. The effect of shelf temperature and chamber pressure on product temperature 
(marked with  gray text  and dashed lines)  and sublimation  rate  during  primary drying.  The  
explanations for markings A through D are given in text.  Adapted with changes from Chang 
and Fisher (1995). 
 
According to the vitrification hypothesis, the high viscosity of the amorphous phase 
slows down the rate of chemical reactions and conformational changes of proteins at 
temperatures under Tg, thus minimizing changes to the native structure during processing, as 
explained in chapter 2.3.3 (Hagen et al., 1995). For this reason it has been assumed that 
exceeding Tg‘ during primary drying might increase the rate of chemical deterioration in 
proteins (Franks, 1998). However, several more recent studies have found no clear difference 
in the extent of protein degradation between samples that have been lyophilized below or 
above their Tg’ during primary drying (Chatterjee et al., 2005; Sarciaux et al., 1999; Schersch 
et al., 2010). Furthermore, it seems that in some cases the storage stability of protein-
structured pharmaceuticals is even better in collapsed lyophilizates than in non-collapsed 





mobility of the glassy state, that occurs as a result of holding the amorphous mixture above 
its Tg during drying, as explained in chapter 2.2.2. Exceeding the glass transition temperature 
at some point during freeze drying may still have a deleterious effect on protein stability, 
however, if the formulation contains only very unstable lyoprotective excipients such as 
mannitol, that have a tendency to crystallize easily when held above their Tg (Izutsu et al., 
1994).  
 
2.4.3 Secondary drying 
After primary drying the lyophilizate consists of solutes that had originally been 
dissolved in water, along with residual water that is either present in solid amorphous phase 
as “plasticizer” or as hydrate in crystalline phase. The main purpose of the third processing 
step, referred to as secondary drying, is therefore to define the amount of the residual water 
that remains in the final product. Water content reduction during secondary drying seems 
mainly to be limited by the rate of water evaporation from lyophilizate surface, even though 
the effect of water diffusion from lyophilizate core to surface may also be significant (Pikal et 
al., 1990). Due to this, product surface area has a greater effect on secondary drying rate than 
lyophilizate thickness. However, it is difficult to decrease overall freeze drying times by 
increasing the product surface area, because as stated in chapter 2.4.1, producing ice crystals 
with smaller average size might lead to decreased sublimation rate during primary drying 
(Searles et al., 2001). Therefore the net effect of decreasing the pore size on the overall drying 
time might even be negative. Furthermore, increasing the diffusion coefficient of water in a 
given formulation without compromising the structural integrity of the lyophilizate (i.e. 
causing collapse) would be challenging. Contrary to common beliefs, chamber pressure does 
not appear to have a significant effect on the drying rate during secondary drying in porous 
lyophilizates (Pikal et al., 1990). This is because once evaporated, water is quickly 
transported through the pores and towards the condenser. 
Drying temperature should be increased in order to facilitate water evaporation, as the 
rate of water evaporation decreases as a function of time under isothermic conditions (Pikal 
et al., 1990). However, as the amorphous phase still contains a significant amount of water 
after primary drying, it is possible to induce partial or complete collapse in the lyophilizate by 
increasing the shelf temperature too rapidly (Franks, 2007; Shalaev and Franks, 1995). In 
order to optimize the effectiveness of a conventional secondary drying step, lyophilizate 
temperature may be increased as water is removed to keep it between Tg and Tc, as shown in 
Figure 10. When drying heat-labile proteins, the use of higher secondary drying temperatures 
or extending the time the formulation spends in high temperatures may result in increased 
protein aggregation (Franks, 2007). On the other hand, using lower temperatures extends the 
time taken to reach adequate residual water content, which may also an increasing effect on 
API degradation (Pikal et al., 1990). Since overdrying can also have a harmful effect on the 
stability of certain proteins (Chang et al., 2005), maximal secondary drying conditions are 








Figure 10. The change in lyophilizate Tg (line AB) and Tc (line CD) as a function of secondary 
drying  time  (or  decreasing  residual  water  content).  A  near-optimal  shelf  heating  rate  of  a  
conventional  freeze  drying  cycle  is  depicted  by  the  gray  dashed  line.  Adapted  with  changes  
from Franks (2007). 
 
2.4.4 Significance of freeze drying as a protein stabilization method 
As should be clear after this chapter, freeze drying may subject a protein to a number of 
different stress factors. In fact, many pharmaceutically relevant proteins can be made 
sufficiently stable in properly formulated aqueous solutions for them to reach an acceptable 
shelf life of 2-3 years at 2-8°C, whereas freezing and dehydration may be harmful for them. 
This, coupled with the fact that freeze drying is a cost-intensive batch-processing method, 
means that it is commonly not the first choice when selecting a stabilization method. 
However, there are reasons why approximately 1/3 of all mAb drug products that have 
received marketing authorization are produced by freeze drying. Some proteins simply are 
not  stable  for  long  periods  of  time  as  aqueous  solutions,  meaning  that  drying  is  the  most  
feasible option to produce a stable product that can be marketed. Also, one drawback of 
aqueous formulations is their susceptibility to shaking-induced degradation, as explained in 
chapter 2.3.1, but this should not occur in freeze-dried products before rehydration. It is also 
possible to develop freeze-dried protein pharmaceuticals that are stable in room temperature, 
such as in the case of the human plasma IgG extract Gammagard® (Baxter International Inc., 
Deerfield, IL, USA) and the INF- 1a product Avonex® (Biogen IdeC Inc., Weston, MA, USA). 
On the other hand, aqueous protein products must typically be kept refrigerated, making 
their transportation and storage more difficult. Compared to other drying methods of 
protein-structured pharmaceuticals, such as spray drying, freeze drying possesses the 
advantages of being commonly accepted by regulatory agencies, allowing relatively easy 
incorporation into aseptic manufacturing lines and not subjecting the product to high 
temperatures. Furthermore, freeze drying does not normally result in material loss during 
processing, which is not always the case in spray drying. While freeze drying affects the 
stability of different proteins in a different way (Prestrelski et al., 1993a), and may therefore 
not be suitable for all protein-structured APIs, it remains a highly important processing tool 





2.5 Excipients used in freeze-dried pharmaceutical products 
 
Protein-protecting excipients in lyophilized formulations are sometimes classified as 
cryo- and/or lyoprotective compounds, depending on whether they protect the API during 
freezing and/or drying, respectively. Theoretically, a cryoprotective excipient could be 
preferentially excluded from the vicinity of the protein, as explained in chapter 2.3.1, and/or 
it could have an amphiphilic molecular structure which allows it to concentrate on ice/water 
interfaces, as explained in chapter 2.3.2. On the other hand, a lyoprotective excipient could 
form a viscous glass during freeze-concentration and thus inhibit the molecular mobility of 
the protein, and/or partially replace water as hydrogen bond former on the hydrophilic 
surface of the protein, as explained in chapter 2.3.3. Naturally, a single compound may 
possess both cryo- and lyoprotective properties. 
The mechanical strength of crystalline compounds is often higher than that of 
amorphous ones due to more organized bond structure. For this reason, easily crystallizing 
excipients, sometimes referred to as bulking agents, can be used to bring mechanical stability 
to otherwise easily crumbling lyophilizates (Shalaev and Franks, 1996). Furthermore, they 
can be used in combination with non-crystallizing protein-protecting excipients to uphold the 
porous lyophilizate microstructure even when Tc of the amorphous phase is exceeded during 
drying (resulting in so-called microcollapse). Employing such drying cycles might have the 
benefit of reducing the molecular mobility of the amorphous phase due to the annealing 
effect, but without significantly lowering drying rates because of decreased lyophilizate 
porosity and surface area. 
Proteins often have an optimal pH range where they are most stable, and it is therefore 
commonplace to add buffering compounds to the solutions to be freeze dried (Wang, 2000). 
As most biopharmaceuticals are administered via injection or infusion (usually IV, SC or IM 
route), it is also necessary to make the formulation as close to isotonic as possible. Both pH 
and tonicity can be adjusted with excipients, but the effects of stability and freeze-
concentration on solution properties must be taken into account. An extensive knowledge of 
the physicochemical properties of the API and excipients is therefore an integral part of the 
development process. Some of the most commonly used excipients are introduced below. 
 
2.5.1 Low molecular weight saccharides and polyalcohols 
Perhaps the most effective cryo- and lyoprotective excipients used in freeze-dried 
protein products are disaccharides. Commonly abundantly present in organisms that often 
experience dehydrating conditions (Crowe et al., 1996), disaccharides such as sucrose and 
trehalose have been studied thoroughly and they are well tolerated also in high doses. 
Furthermore, they can act as both cryo- and lyoprotective excipients, as they are 
preferentially excluded in aqueous solutions (Timasheff, 1998) and form viscous glasses 
(Hagen et  al.,  1995)  with a  high hydrogen bonding potential  with the protein in  solid  state  
(Carpenter and Crowe, 1989). The disaccharides used in freeze-dried mAb products are 
currently limited to sucrose and trehalose (Wang et al., 2007), but maltose is used in the 
aqueous tositumomab / I131 tositumomab drug product Bexxar® (GlaxoSmithKline plc, 
Middlesex, UK). The glass-forming properties of disaccharides distinguish them from 
monosaccharides, whose freeze-concentrated aqueous solutions generally exhibit too low Tg’ 
for them to be useful as freeze drying excipients in conventional formulations (Roos, 1997), 
where lyophilizate collapse is an undesired phenomenon. Similarly, even though polyalcohols 





induced stress, their high crystallization tendency reduces their suitability as the only 
lyoprotecting excipient in a formulation. However, their tendency to crystallize makes 
polyalcohols effective bulking agents, and this may be one of the main roles of mannitol in 
the basiliximab-containing drug product Simulect® (Novartis International AG, Basel, 
Switzerland), where it is used in combination with the cryo-/lyoprotecting excipient sucrose. 
Some physical properties of low molecular weight saccharides and polyalcohols are shown in 
Table 2.  
Even though protein stability during freeze drying and subsequent storage is often 
dependent on the excipient/protein ratio, using higher saccharide concentrations does not 
always result in better protein recovery after rehydration. For example, a minimum effective 
disaccharide/protein molar ratio of 360/1 was determined for a freeze-dried monoclonal 
antibody, and increasing the excipient concentration above this no longer improved protein 
stability (Cleland et al., 2001). Also, utilizing a combination of two protein-protecting 
excipients, such as a disaccharide and polyethylene glycol (PEG), may result in better 
retention of the native protein structure during freeze drying than by using only the 
disaccharide (Prestrelski et al., 1993b).  
 
Table 2. Physicochemical  properties  of  some  low  molecular  weight  saccharides  and  
polyalcohols that have been studied as freeze drying excipients. Data gathered from 
publication II, Franks (2007), Kim et al. (1998), Lopes Jesus et al. (2010), Piedmonte et al. 
(2007), Roos (1997), Taylor and Zografi (1998) and from unpublished results. It should be 
noted that even thought all Tg and Tg’ values have been measured with DSC, the measurement 
methods may vary. 
 
Name Class Tg Tg’ 
Reducing/non-
reducing* 
     
cellobiose disaccharide 108°C -30°C reducing 
erythritol polyalcohol -44°C N.A.** non-reducing 
glucose monosaccharide 39°C -43°C reducing 
isomalt polyalcohol 63°C -33°C non-reducing 
isomaltulose disaccharide 31°C -35°C reducing 
lactitol polyalcohol 65°C -32°C non-reducing 
lactose disaccharide 114°C -28°C reducing 
lactulose disaccharide 79°C -31°C reducing 
maltitol polyalcohol 15°C -35°C non-reducing 
maltose disaccharide 95°C -29°C reducing 
mannitol polyalcohol 13°C -30°C non-reducing 
melibiose disaccharide 100°C -30°C reducing 
raffinose trisaccharide 109°C -26°C non-reducing 
sorbitol polyalcohol -3°C -45°C non-reducing 
sucrose disaccharide 74°C -32°C non-reducing 
trehalose disaccharide 119°C -28°C non-reducing 
     
*  here  a  compound  is  considered  reducing,  if  it  participates  in  Maillard  reaction  with  an  
amino acid with a rate that may be pharmaceutically relevant. 
** Tg’ of erythritol was not found in literature and could not be measured due to its high 
crystallization tendency from aqueous solutions during freezing. 
 
The use of reducing sugars in protein pharmaceuticals is commonly discouraged 





nature, are the most commonly used disaccharides in such products. Reducing sugars 
contain a free hemiacetal or hemiketal group, which means that the molecule coexists as both 
closed  ring  and  open  chain  forms  (Martins  et  al.,  2001),  as  shown  in  Figure  11.  The  open  
chain form contains a reducing aldehyde or ketone group, which may participate in Maillard 
reaction, a form of non-enzymatic browning, by reacting with the free amino groups of 
proteins, usually in lysine or in a terminal amino acid, to form an N-substituted 
glycosilamine intermediate molecule. This can then take part in a number of chemical 
reactions via several reaction pathways, that ultimately lead to the formation of melanoidin 
co-polymers and brown nitrogenous polymers (hence the name non-enzymatic browning). In 
the case of mAbs, Maillard reaction can lead to the loss of positive charges on protein 
surfaces and the formation of acidic species (Wang et al., 2007). The reaction can take place 
in both aqueous and dried solid protein formulations, but the reaction kinetics generally 
appear to be fastest in moist amorphous mixtures with aw around 0.4 – 0.6, which are stored 
above their Tg (Bell, 2007). On the other hand, the rate of Maillard reaction may be reduced 
by lowering the pH of the formulation, because the reactive open chain form of the sugar and 




Figure 11. The conversion between cyclic (left) and open-chain (right) forms of the glucose-
monomer of melibiose (6-O- -D-galactopyranosyl-D-glucopyranose), a reducing 
disaccharide. Anomeric conversion between - and -melibiose is not shown. 
 
2.5.2 Surfactants 
Non-ionic surface active agents (surfactants) are sometimes used in freeze drying to 
reduce protein denaturation on ice/water interface (see chapter 2.3.2). Because they contain 
both polar and non-polar moieties, surfactants tend to concentrate on such interfaces and 
prohibit protein interaction with the denaturating surface (Liu et al., 2005). For this reason 
they can be effective as cryoprotectants, but may possess limited lyoprotecting properties 
(Luthra et al., 2007), possibly due to relatively poor hydrogen bond and glass forming 
properties. Most commonly used surfactants include polysorbate (PS) 20 and 80 (Kerwin, 
2008). 
 
2.5.3 Salts and buffers 
Salts such as NaCl or KCl may be included in formulations to assure that the solution 
becomes as isotonic as possible upon reconstitution. This is not the only application for salts, 
however, as they can be used for other purposes as well. For example, NaCl has been shown 
to decrease the aggregation of freeze-dried tetanus toxoid during storage when compared to 
excipient-free samples (Schwendeman et al., 1995). Because of its high crystallization 





mechanical stability of lyophilizates (Shalaev and Franks, 1996), even though this is not a 
common formulation strategy.   
As explained in chapter 2.3.1, formulation pH is an important factor when determining 
the optimal stability conditions for a protein pharmaceutical. The selection of buffering 
compounds should be rationalized, however, as some commonly used buffers may crystallize 
during freeze-concentration, leading to pH shifts as explained in chapter 2.3.2 (Bhatnagar et 
al., 2007). Since solute crystallization is normally caused by supersaturation, an obvious 
solution is to use as low buffer concentrations as possible (Kasper and Friess, 2011), but this 
may  not  solve  the  problem  for  all  buffering  compounds.  For  example,  disodium  hydrogen  
phosphate dodecahydrate (Na2HPO4·12H2O) often crystallizes due to freeze-concentration 
when sodium phosphate buffers are frozen (Gomez et al., 2001). The resulting pH shift may 
be significant, and a decrease of even 2 units in 8 mM phosphate buffer solutions during 
freezing is possible. Na2HPO4·12H2O crystallization can also occur in even more dilute 
solutions than this, as crystalline disodium hydrogen phosphate dodecahydrate has been 
detected in 1 mM phosphate buffer solutions after freezing to -50°C (Varshney et al., 2006). 
What makes the detection of such buffer crystallization difficult is that the freeze drying end 
product  may  be  totally  amorphous.  This  is  because  even  though  Na2HPO4·12H2O tends to 
crystallize during freezing, the dehydration of the dodecahydrate during primary drying may 
result in amorphicization of the crystals (Pyne et al., 2003). Nonetheless, the pH shift 
experienced during freezing may still be detrimental for protein stability. Other buffers that 
do not crystallize as easily, such as those containing citrate ions (Chang and Randall, 1992), 
may be more suitable for formulations which are frozen at some point during production or 
storage. Despite this, sodium phosphate buffers are still sometimes used in freeze-dried 
formulations, such as in the case of infliximab-containing product Remicade® (Janssen 
Biotech Inc., Horsham, PA, USA). 
 
2.5.4 The need for new excipients for protein formulations 
The number of excipients that are commonly used in freeze-dried protein-structured 
drug products is relatively small. Furthermore, some of those commonly used are 
problematic due to their seemingly sporadic behaviour during freezing, such as is the case 
with mannitol (Kim et al., 1998) and sodium phosphate buffers (Gomez et al., 2001). As the 
previous chapters have stressed, protein formulations tend to be highly unstable systems and 
their stabilization may be difficult. Therefore, increasing the number of excipients that could 
be employed in such formulations might make the work of formulation scientists easier. The 
problem regarding the use of new compounds as pharmaceutical excipients is that 
comprehensive toxicity studies would have to be carried out before a marketing authorization 
for a product containing them could be obtained. These are very expensive to perform, which 
means that only very promising compounds should be studied in clinical trials. In a highly 
unappealing scenario, a potential new excipient would be taken through toxicity studies only 
to find that there already was an excipient on the market which performs better. On the other 
hand, carrying out comprehensive in vitro feasibility studies for potential new excipients 
where their protein-protecting efficacy would have been proven before initiating clinical trials 
would reduce the risk of this kind of disaster. For this reason, this thesis focuses on 
comparing the efficacies of potential freeze drying excipients, some of which have not yet 
been tested in clinical toxicity trials. 
 
 




3 Aims of the study 
 
 
The aim of the thesis project was to study the mechanisms affecting the performance of 
disaccharides and polyalcohols as protein-protecting excipients during freeze drying and the 
subsequent storage. Since a given compound may not stabilize different proteins with 
comparable efficacy, three different model proteins were employed during the course of these 
studies. In addition to being studied in protein-containing formulations, the behavior of 
some of the excipients was explored in pure amorphous form, so that the physical properties 
of the protein-protecting compounds themselves could be compared.  
 
 
More specifically, the aims of the present study were to: 
 
 
 Show that structurally dissimilar disaccharides and polyalcohols exhibit different 
efficacies in protecting -galactosidase from degradation during freeze drying and the 
subsequent storage at an elevated temperature, and that these efficacies can be 
predicted to some extent based on their molecular structures and physical properties 
(I,II) 
 
 Demonstrate that the physical stability of structurally comparable disaccharides may 
vary during storage at different relative humidity atmospheres, and that the molecular 
mobility and crystallization tendency of a given excipient can affect its protein 
stabilization performance (I,II) 
 
 Show how the interplay of freeze drying parameters and formulation composition 
may sometimes affect the stability of polyclonal IgG during drying (III) 
 
 Prove that the efficacy of a reducing disaccharide (melibiose) in protecting rituximab 
from degradation can in some cases be equal to or better than that of a non-reducing 
disaccharide (trehalose) during freeze drying and the subsequent storage at different 












4.1 Materials, formulations and protein purification (I-IV) 
 
The cryo-/lyoprotecting excipients used in the studies are given in Table 3. -D-
galactosidase (I) from Aspergillus oryzae (Mw   125  kDa,  activity  NLT  76.5  U/mg)  was  a  
kind gift from Amano Enzyme Inc. (Nagoya, Japan), and the protein was purified by using 
tangential flow filtration (TFF). Pall Minimate TFF system (Pall Co., NY, USA) with Omega 
30 K molecular weight cutoff (MWCO) filter was employed with continuous filtration method 
using purified water as the filtration medium and by collecting 7 diafiltration volumes. After 
filtration the protein solution was diluted to 0.5 mg/ml concentration with purified water, 
and excipients (Table 3) were added to produce 1 mg/ml, 10 mg/ml and 20 mg/ml solutions 
(corresponding to 730:1, 7300:1 and 15000:1 excipient/protein molar ratios, respectively). 
The solutions were freeze dried according to the cycle given in chapter 4.2.1. 
 
Table 3. The names and types (R = reducing, NR = non-reducing) of the cryo-/lyoprotecting 
excipients  used  in  the  studies,  along  with  the  purities  of  the  raw  materials  (as  given  by  the  
suppliers), suppliers and trade names (if available). Furthermore, the individual studies where 
the excipients in question were used are expressed using the roman numerals I – IV. 
 
Name Type Purity Supplier / Trade name  Used in 
     
cellobiose disaccharide (R) > 98 % Sigma-Aldrich Co. (I,II) 
erythritol polyalcohol (NR) > 99 % Cargill Inc. /  C*Eridex (I) 
isomalt polyalcohol (NR) > 99 % Palatinit GmbH / galenIQ 720 (I) 
isomaltulose disaccharide (R) > 99 % Cargill Inc. /  Xtend (I) 
lactitol polyalcohol (NR) > 99 % Danisco A/S / Lactitol MC (I) 
lactulose disaccharide (R) > 98% Sigma-Aldrich Co. (I) 
maltitol polyalcohol (NR) > 76%* Cargill Inc. / C*Pharm Maltidex (I) 
mannitol polyalcohol (NR) > 99 % Cargill Inc. / C*Pharm Mannidex (I) 
melibiose disaccharide (R) > 98 % Sigma-Aldrich Co. (I,II, IV) 
sucrose disaccharide (NR) > 99 % Sigma-Aldrich Co. (I,II) 
trehalose disaccharide (NR) > 99 % Sigma-Aldrich Co. (I,II, III, IV) 
     
*  maltitol  was  supplied  as  an  aqueous  syrup  containing  >76%  maltitol,  as  well  as  <  2.5%  
sorbitol  and  <  0.2%  reducing  sugars  as  impurities.  The  syrup  was  dried  in  vacuum  oven  
before use.  
 
Polyclonal bovine serum IgG (III) was obtained from Innovative Research Inc. (MI, 
USA), and the freeze-dried formulation consisted of 1 mg/ml IgG, 5 mg/ml trehalose, 0.01 
mg/ml bovine serum albumin (BSA) and 15 mM Nacl in 1 mM Na-phosphate buffer (pH 7.4). 
In order to test the effects of individual excipients on IgG stability, the formulation was 
fractionated using size exclusion columns containing cross-linked dextran beads (HiTrap® 
Desalting column, GE Healthcare Biosciences Corp., NJ, USA) to remove the other excipients 
besides BSA. After fractionation, trehalose, NaCl and/or Na-phosphate buffer were added to 
create new formulations. The solutions were filtered through 0.2 µm polyethersulfone (PES) 





into 10 ml blow-molded vials, where they were freeze dried according to the cycle given 
below. 
Rituximab (IV) (MabThera®,  F.  Hoffmann  –  La  Roche  Ltd.,  Basel,  Switzerland)  was  
kindly  donated  by  the  Helsinki  University  Central  Hospital.  In  addition  to  10  mg/ml  of  
rituximab, MabThera® also contains 7.35 mg/ml sodium citrate, 9 mg/ml sodium chloride 
and 0.7 mg/ml PS80 as excipients. The removal of the original formulation excipients was 
attempted by fractionating MabThera® with PD-10 size-exclusion columns (Sigma-Aldrich 
Co.,  St.  Louis,  MO,  USA)  by  using  10  mM  citrate  buffer  (pH  6.3)  as  the  eluent.  The  
effectiveness of the fractionation protocol in removing PS80 from the protein solution was 
measured using the RP-HPLC quantitation method developed by Adamo et al. (2010). The 
protein concentration of the filtrate was measured with a UV-spectrophotometer at 280 nm 
by using an extinction coefficient of 1.49 ml mg 1 cm 1 (Hawe et al., 2010). The rituximab 
solutions were diluted to 1 mg/ml concentration with 10 mM citrate buffer (pH 6.3) and 
trehalose or melibiose was added to produce two formulations with 1 mg/ml rituximab, 10 
mM citrate buffer and 50 mg/ml of either trehalose or melibiose. The solutions were freeze 





4.2.1 Freeze drying (I-IV) 
-galactosidase (I),  polyclonal  bovine  serum  IgG  (III)  and  rituximab  (IV) solutions 
were freeze dried using Lyostar II lyophilizer (SP Industries Inc., Warminster, USA). Pure 
disaccharide samples (II) were pre-frozen in two different freezers at -20°C and -80°C for 24 
h each, and then freeze dried using Lyovac GT2 freeze drier (Amsco Finn-Aqua GmbH, 
Germany) for 72 h at 150 mT. The resulting lyophilizates were further equilibrated under 
vacuum in desiccators containing phosphorous pentoxide (P2O5) for one week to further 
reduce their residual water contents before initiating the storage experiments. The freeze 
drying cycles used in different studies are given in Table 4. In study (III) the primary drying 
pressure and secondary drying heating rate were altered between three different processing 
values, denoted by numbers -1, 0 and 1. In studies (I) and (III) the sample temperatures were 
measured during drying with thermocouples, which were inserted into the vials so that they 
were in direct contact with the solutions being freeze dried. The drying chamber was filled 
with dry N2 after each freeze drying cycle, and the vials closed by either compressing the vials 
inside the chamber (I, III), or by fixing the stoppers immediately after sample removal (II, 
IV).  
 
4.2.2 Sample storage 
-galactosidase lyophilizates (I) were rehydrated with purified water and analyzed after 
freeze drying, or after being stored for 7, 30 or 90 days in closed vials at 45°C. This storage 
temperature was used, because it has been employed earlier to bring out the differences in 
storage stabilities of different -galactosidase strains (Palumbo et al., 1995). Pure 
disaccharide lyophilizates (II) were stored in open vials at ambient temperature in 
desiccators containing different relative humidity atmospheres (RH 0%, 11%, 23%, 33% and 
43%) for up to 46 days and analyzed periodically. Higher relative humidity atmospheres, e.g. 
RH 60% as is suggested by the ICH guideline Q1A-R2 (ICH, 2003), were not used, because 





above their collapse point was not considered relevant in these experiments. Polyclonal 
bovine serum IgG lyophilizates (III) were analyzed after freeze drying without subjecting 
them to a specific storage period. Rituximab lyophilizates (IV) were rehydrated with 0.22 µm  
filtered purified water and analyzed after freeze drying, or after being stored for 30, 60 or 90 
days at 25°C in loosely stoppered vials to allow moisture sorption to occur in desiccators 
containing different relative humidity atmospheres (RH 5%, 11% and 23%). Storage 
conditions mimicking room temperature (i.e. 25°C) were used instead of those representing 
refridgerated conditions (i.e. 2-8°C) in order to increase the rate of protein degradation 
reactions. 
 
Table 4. The freeze drying cycles used in different studies, where shelf temperatures (Tshelf), 
stage times (t) and chamber pressures (P) of different drying stages were altered according to 
the scheme shown in the table. Study (II) was carried out using a drier without Tshelf control. 
 
Study Freezing Primary drying Secondary drying 
 Tshelf ; t Tshelf ; t ; P Tshelf ; ( )t ; P 
    
(I) 1) 5°C ; 0.5 h 35°C ;21 h ; 150 mT 1)  35°C at 5°C / h ; 150 mT 
 2) 45°C ; 2 h  2) 35°C ; 2 h ; 150 mT 
 3) 40°C ; 0.5 h   
    
(II) 1) -20°C ; 24 h - ; 72 h ; 150 mT  - 
 2) -80°C ; 24h   
    
(III) 40°C ; 3.5 h -1: 25°C ; 21 h ; 20 mT -1:  40°C at 5°C / h ;60 mT 
  0: 25°C ; 21 h ; 60 mT 0:  40°C at 30°C / h ;60 mT 
  1: 25°C ; 21 h ; 100 mT 1:  40°C at 60°C / h ;60 mT 
   (total sec. drying time always 16 h) 
    
(IV) 1) 5°C ; 0.5 h 40°C ; 25 h ; 100 mT  20°C at 2.5°C / h ; 100 mT 
 2) 45°C ; 3 h   
    
 
4.2.3 Protein in vitro activity and binding analysis (I, III) 
-galactosidase activity (I) after freeze drying and storage was measured with 
spectrophotometric o-nitrophenyl- -D-galactopyranoside (ONPG) cleavage rate test (n = 3) 
at 420 nm (Sambrook et al., 1989). The results were compared to a standard curve, and the -
galactosidase activity after TFF purification was assigned as 100% in relative activity. The 
purity of the filtered -galactosidase solution was not examined, because for the sake of 
comparing the protein-protecting efficacies of different excipients, it was not necessary to 
fully characterize the filtrate. Polyclonal bovine serum IgG (III) in vitro binding activity was 
measured with enzyme-linked immunosorbent assay (ELISA) in 96-well plates using a 
commercial polyclonal ELISA test (Bethyl Laboratories Inc., TX, USA). The plates were 
coated with bovine IgG, washed and then blocked with PS20. Lyophilizates (n = 3) were 
rehydrated with 1 ml purified water, equilibrated for 60 min and diluted before incubation on 
the coated well plates. After incubation, the wells were washed, incubated with horseradish 
peroxidase -conjugated IgG, washed again and finally incubated using tetramethylbenzidine 





measured at 450 nm using an automated well plate reader (Varioskan 3001, Thermo Fisher 
Scientific, MA, USA). The results were compared to a standard curve, which was generated 
separately on each well plate from a reference bovine IgG solution. All well plate pipetting 
and washing was carried out by using an automated work station (TECAN Genesis RPS 
8/150, Tecan Group Ltd., Switzerland) in order to minimize the effect of pipetting errors. 
 
4.2.4 Lyophilizate solid state analysis (I-IV) 
Lyophilizate Tg and aqueous formulation Tg’ values were measured by using differential 
scanning calorimetry (DSC) with DSC823e (Mettler Toledo Inc., Zürich, Switzerland) (I - 
IV). The samples enclosed in hermetically sealed 40 µl aluminum pans, equilibrated at a 
given temperature for 3-10 min and heated at 10°C/min under 50 ml/min dry N2 flow to  a  
given temperature. Tg and Tg’ values were taken as transition midpoints. 
Lyophilizate crystallinity was studied with x-ray powder diffractometry (XRPD) by 
using Bruker D8 Advance (Bruker AXS Inc., WI, USA) (I, II, IV). The samples were scanned 
along a  given 2  range at  0.05°  -  0.1°/s  rate.  If  a  crystal  diffractogram was detected,  it  was  
compared to calculated diffractograms acquired from Cambridge Structural Database (CSD) 
by using ConQuest 1.10 program (Cambridge Crystallographic Data Centre, Cambridge, UK) 
in order to identify the polymorph(s) in question. 
Lyophilizate water contents were measured with two different methods. Volumetric 
Karl-Fisher titration (KF) with MT-V30 (Mettler Toledo, Switzerland) was used to analyze 
the larger lyophilizates (II, IV), and thermogravimetric analysis (TGA) with TGA 850 
(Mettler-Toledo Inc., Switzerland) was used in the case of smaller samples (I, III). In KF 
measurements the lyophilizates were ground in a glovebox under low relative humidity (  
5%) before transferring them to the measurement cell in order to increase sample dissolution 
rate. TGA measurements were carried out by weighing 5-10 mg of sample into 70 µl alumina 
crucibles, equilibrating it at 25°C for 5 min and then heating at 20°C/min to 120-130°C under 
50  ml/min  dry  N2 flow, where the sample was again equilibrated for 5 min. The water 
contents were calculated from the resulting weight losses. 
Lyophilizate water sorption rates were studied by using two different methods. In 
desiccator measurements the water contents were determined gravimetrically (n = 4), after 
having measured the empty vial masses, as well as the initial lyophilizate water contents by 
using KF. In addition, isothermal microcalorimetry (IMC) was performed with TAM 2277 
(Thermometric AB, Sweden). The IMC included a sequential RH-unit setup, where a gas flow 
with controlled relative humidity was first directed to the calorimeter cell containing the 
sample (n = 1). The gas flux exiting the sample cell was then lead to a second cell, where it 
was moistened to RH 100% while measuring the moisturization heat. As a result, the sample 
water sorption and desorption could be observed in addition to other thermodynamic 
transitions occurring in the sample. The ground lyophilizate samples were ramped from RH 
0% to RH 60-70% at 25°C by 10% increases every 4 h, while continuously measuring changes 
in heat flow. 
 
4.2.5 Sample visualization (II) 
In order to study whether viscous flow had occurred in amorphous lyophilizates during 
processing and storage, pure disaccharide samples were analyzed with scanning electron 
microscopy (SEM). The samples were coated with a thin platinum layer in Quorum Q150TS 





FEG (FEI Inc., OR, USA) microscope under 60 Pa pressure with large field vacuum 
secondary electron detector. 
 
4.2.6 Molecular mobility measurement (II) 
Relaxation time constants relating to the molecular mobility of freeze-dried trehalose 
and melibiose lyophilizates were measured after their water contents had been equilibrated 
to a given level. Solid-state NMR (ssNRM) cross polarization magic angle spinning (CPMAS) 
experiments were carried out using Bruker Avance III 500 spectrometer (Bruker BioSpin 
GmbH,  Ettlingen,  Germany)  with  magnetic  flux  density  of  11.7  T,  and  with  4  mm  double  
resonance broad band VTN CPMAS probehead. Samples (n = 1) were packed into ZrO2 rotors 
plugged with KEL-F endcaps, and the sample spinning rate was set to 10 kHz. The 
longitudinal relaxation time constants of protons (T1H) were measured at 35°C by using a 
saturation recovery experiment with cross polarization step and carbon detection. Contact 
time for cross polarization was 500 s, and the signal acquisition time was 10 ms, during 
which  proton  decoupling  (SPINAL-64)  with  a  rf-field  strength  of  63  kHz  was  used.  The  
spectra were referenced externally via adamantane by setting the low field resonance at 38.48 
ppm. The intensity of the largest signal that was found in the spectrum close to 72 ppm for 
trehalose and 70 ppm for melibiose was measured at eight delay times after the saturation 
step. An exponential fit of the obtained data was carried out by using TopSpin 2.1 software 
(Bruker BioSpin GmbH, Ettlingen, Germany). 
 
4.2.7 Protein secondary structure analysis (I, III, IV) 
Fourier transform infrared (FT-IR) spectroscopy was used to study -galactosidase 
secondary structure directly from the lyophilizates (I). 1-2 mg of the lyophilizate (n = 5) was 
ground  with   250  mg  of  FT-IR  grade  KBr  (221864,  Sigma-Aldrich,  MO,  USA)  and  
compressed into a pellet under vacuum. The samples were analyzed using Vertex 70 (Bruker 
Optics Inc., MA, USA) FT-IR spectrometer by measuring the spectra 20 times with 4 cm-1 
resolution between 4000-650 cm-1 under dry air flow. The spectra were further treated using 
OPUS 4.0 program (Bruker Optics Inc., MA, USA) by calculating their second derivatives, 
after which they were smoothed with Savitzky-Golay function by using a convolution width of 
9 points. The resulting spectra were baseline corrected along 1720- 1490 cm-1 region (amide I 
and II regions) to minimize the effect of differing baselines on further data analysis.  
Far-UV circular dichroism (CD) spectra of rehydrated samples (n = 1-2) were measured 
using Jasco J-720 (III) or J-815 (IV) CD spectrometers, which used Jasco PTC-4235 units to 
control the measurement temperature (Jasco International Ltd., Tokyo, Japan). The samples 
were diluted to 0.1 mg/ml protein concentration and the spectra were measured from a 1 mm 
path length quartz cuvette in the far-UV region at 25°C temperature. The scan rate varied 
between 12 - 200 nm/min and each final spectrum was averaged from 5-6 consecutive scans. 
The resulting spectra were background corrected by subtracting the corresponding blank 
buffer spectrum from the result, and either used as such (III) or after being smoothed with 
Savitzky-Golay function by using a convolution width of 25 points (IV). Finally, the CD 
signals were converted to mean residual ellipticity (MRE) according to Kelly et al. (2005). 
 
4.2.8 Protein aggregation, fragmentation and monomer recovery analysis (III, IV) 
The concentrations and size distribution of particles with a diameter between 1 – 100 
µm  (IV) were measured from rehydrated solutions with light obscuration (LO) by using 





Rutesheim, Germany). Samples (n = 3) were measured three times with a sample volume of 
0.2 ml per measurement, using emptying and rinsing rates of 10 ml/min. Prior to each 
measurement the system was flushed with 0.22 µm syringe-filtered purified water until 
particle counts of less than 50 particles/ml 1 µm and less than 10 particles/ml 10 µm were 
reached.  
Dynamic light scattering (DLS) measurements were performed with a Malvern 
Zetasizer  3000  HS  (III) or Zetasizer Nano ZS (IV) (Malvern Instruments Ltd., 
Worcestershire, UK). The measurements (n = 3-6) were carried out from rehydrated 
solutions at 25°C in single-use polystyrene cuvettes (Fisher Emergo B.V., Landsmeer, the 
Netherlands) with a path length of 10 mm. 3x10 runs of 60 seconds each (III) or 3x15 runs of 
10 seconds each (IV) were performed, and the average intensity size distributions, Z-average 
diameters (Z-ave) and polydispersity indexes (PDI) of the formulations were obtained. 
Nanoparticle tracking analysis (NTA) of the particles with a diameter between 50 – 
1000 nm (IV) was performed by using NanoSight LM20 (NanoSight Ltd., Amesbury, UK), 
equipped with a 640 nm laser and a Viton fluoroelastomer O-ring. The benefits and 
limitations of NTA as a counting and sizing method for protein aggregates has been discussed 
in detail elsewhere (Filipe et al., 2010a). The particle counts and size distributions of 
rehydrated samples (n = 2) were analyzed with three 40 second measurements. Detection 
threshold was varied between 5 – 20 and gain between 0.5 – 3 depending on the particle 
content of samples. When necessary, samples were diluted to limit the maximum number of 
particles per images to  50. Minimum particle size was set to 50 nm to exclude potential 
error signals caused by large rotating irregular particles. Prior to each measurement the 
system was flushed with 0.22 µm syringe-filtered purified water. The mean particle sizes and 
particle concentrations were calculated with NTA 2.0 software (NanoSight Ltd., Amesbury, 
UK). 
The changes in soluble polyclonal bovine IgG monomer contents (III) were studied 
with asymmetric flow field flow fractionation (AF4). AF2000 (Postnova Analytics, Lansberg, 
Germany) model AF4 was connected to UV detector (PN3211, Postnova Analytics, Lansberg, 
Germany) at 280 nm wavelength for protein concentration analysis. Lyophilizates were 
rehydrated using 1 ml of purified water and equilibrated at room temperature for 60 min 
before injection. The eluent (8.5 mM phosphate buffer with 150 mM NaCl and 0.02%-w/w 
NaN3, at pH 7.4) and the sample solution (protein concentration 1 mg/ml, injection volume 
50  µl,  n  =  3)  were  delivered  to  the  inlet  of  the  AF4  channel  at  the  rate  of  0.2  ml/min.  
Focusing time was 4 minutes, during which the focusing flow was 4.8 ml/min, the cross flow 
was 4.0 ml/min while the rest of the eluent (at 1.0 ml/min) exited through the channel outlet 
towards the detectors in order to make the solution pass continuously through the detectors. 
The transition time from injection/focusing to elution was 1.0 min, and during elution the 
focusing flow was stopped and eluent flow rate increased to 5.0 ml/min. The channel outlet 
and the cross flow rates were 1.0 and 4.0 ml/min, respectively. Elution stage lasted 40-90 
minutes depending on the sample, and the resulting data was further treated using NovaFFF 
software (Postnova Analytics, Lansberg, Germany).  Soluble IgG monomer contents were 
calculated by comparing the maximum monomer UV signal peak height of the native samples 
to those of the freeze-dried samples. 
High-performance size-exclusion chromatography (HP-SEC) of rehydrated rituximab 
samples (IV) was performed on an Agilent 1200 chromatography system, that was equipped 
with UV and fluorescence detectors (Agilent Technologies, Palo Alto, USA), as well as 
DAWN® HELEOSTM multi angle laser light scattering (MALLS) detector (Wyatt Technology 





phosphate buffer (pH 7.1), 100 mM Na2SO4 and 0.02%-w/w NaN3. Sample injection volume 
was 50 µl with 0.5 mg/ml protein concentration, and separation was carried out at 0.5 
ml/min for 40 minutes using a TSKgel 3000 SWXL 7.8 mm x 300 mm column with a TSKgel 
4000 SWXL guard  column  (Tosoh  Bioscience  Corp.,  Tokyo,  Japan).  Samples  (n  =  3)  were  
centrifuged at 8000 rpm for 5 min before injection to protect the columns from large 
insoluble aggregates. UV detection was performed at 280 nm, and soluble rituximab 
monomer content was calculated by comparing the area under the curve (AUC) of the 
monomer peak in the freeze-dried samples to that of the unstressed one (which was set at 
100%). Similar method has been used by other studies, where protein monomer contents 
before and after processing has been compared (Cleland et al., 2001; Hawe et al., 2009, 
Schersch et al., 2010). Fluorescence excitation was carried out at 280 nm and emission was 
measured at 350 nm. The light scattering data was used to calculate protein molar masses at 
different retention times by using Astra V software (Wyatt Technology Europe GmbH, 
Dernbach, Germany). 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of rehydrated 
samples (IV) was carried out using Mini-PROTEAN® tetra cell gel electrophoresis system 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Samples that were pretreated under 
reducing (with -mercaptoethanol) and non-reducing conditions (n = 1), were ran on Bio-
Rad Mini-PROTEAN TGX 4-15% tris-glycine precast gels along with Bio-Rad prestained 
broad range SDS-PAGE standards (Mw-range  6 – 200 kDa). The gels were run for 
approximately 30 minutes, and after electrophoresis the gels were stained for 15 minutes 
with Coomassie Brilliant Blue (Bio-Rad Laboratories Inc., Hercules, CA, USA), and destained 
overnight with 10% V/V methanol, 10 % V/V glacial acetic acid and 80% V/V water solution. 
Finally, the destained gels were scanned and the molecular weights of different protein 
species were calculated based on the standard lanes. 
 
4.2.9 Multivariate and statistical analysis (I, III) 
Multivariate data analysis (partial least squares, PLS) of the -galactosidase FT-IR 
spectra (I) was carried out using Simca-P® 10.5 program (Umetrics AB, Umeå, Sweden). 
Differences between spectra were visualized by plotting their principal components (PC) on a 
coordinate system, resulting in a scope plot where each PC was represented by a different 
axis. Therefore, two identical spectra with identical PCs would be superimposed on the score 
plot. The PLS model was also be used to identify which sections of the spectra had the 
greatest impact on different PCs using the loadings plot. In the case of FT-IR spectra, the 
wave number regions which underwent significant changes displayed large loading values. 
This allowed the loadings plots to be used in conjunction with the score plots for the 
identification and interpretation of spectral changes from very large amounts of data. 
Polyclonal IgG freeze drying experimental design and data analysis (III) was carried 
out by using Modde® 7.0 software (Umetrics AB, Umeå, Sweden). A randomized face-
centered central composite design (CCF) setup was created, where two factors, primary 
drying pressure (Pprim) and secondary drying heating rate ( Tsec), were varied on three 
levels (Table 4), and by evaluating cycle-to-cycle variation from three midpoint repeats 
(Pprim = 60 mTorr, Tsec = 30°C/h). Six analytical responses (see chapter 5.4) were 
employed in the characterization of protein stability, and a PLS model was formed to evaluate 
the statistical significance of each response with 95% confidence level. The models were 
evaluated based on the goodness of fit (R2) and goodness of prediction (Q2) values of different 
responses. R2 represents the percentage of variation in the results explained by the model 
(i.e.  how  well  the  data  fits  the  model),  whereas  Q2 shows  the  efficacy  of  the  model  in  




predicting new data (i.e. how well experimental variation is predicted). The limit of p < 0.05 
was used when evaluating whether model could be generated where a factor contributed 
significantly to the variation of a response. 
 
 
5 Results and discussion 
 
 
5.1 General remarks 
 
Using three different model proteins during the course of these studies served several 
purposes. Firstly, using only one model protein would have limited the evaluation of the cryo-
/lyoprotecting properties of different excipients to that particular protein, making the 
generalization of the results difficult. Also, prior to these studies no published results could 
be found regarding the stability of rituximab during freeze drying, whereas -galactosidase 
from different sources has been frequently employed in drying studies (Pikal-Cleland and 
Carpenter, 2001; Vasiljevic and Jelen, 2003; Yoshioka et al., 2007). Therefore it was easier to 
study a large number of excipients using a model protein where ample stability data was 
readily available. The selection of freeze drying parameters for the final stability study with 
rituximab was carried out with polyclonal bovine IgG, because it was relatively easy to 
acquire in quantities that were needed for the process optimization studies (> 1 g). Finally, 
using a pharmaceutically relevant protein (rituximab) was necessary to establish a proof-of-
concept for the use of melibiose in further freeze drying studies of protein-structured 
pharmaceuticals. 
In addition to many relatively poorly studied compounds, the excipient list (Table 3) 
also contained some well-known freeze drying excipients, such as trehalose, sucrose and 
mannitol. This was necessary, because one aim of this study was to establish some kind of 
ranking order within the group of compounds used. If such a ranking order would have been 
created without including certain “golden standards”, the results might have remained a 
curiosity with little practical value. Now, the results are intended to be more comparable with 
other freeze drying studies that deal with the use of excipients in improving protein stability. 
 
 
5.2 Initial excipient comparison and the selection of compounds for further 
studies (I) 
 
The focus of the initial study was to select a number of interesting cryo-/lyoprotective 
excipients for further studies. This selection was carried out by investigating how a model 
protein ( -galactosidase) was protected during freeze drying and storage by different 
compounds. 
 
5.2.1 The enzymatic activity of -galactosidase after freeze drying 
The relative enzymatic activity of -galactosidase remaining in different freeze-dried 
formulations after drying and the subsequent storage at 45°C are shown in Figure 12. It can 
be seen that without any cryo-/lyoprotecting excipients, protein activity was only 
approximately 13% after freeze drying, and no activity was detected after storing it for 7 days 




or longer. This meant that the protein was highly unstable when not protected by an 
excipient. On the other hand, activity after freeze drying was usually > 90% when an 
excipient was used, except in the case of mannitol and erythritol, where it was < 50%. Most 
differences between excipients became visible during storage. The relative activity 
preservation after 90-day storage period was generally good when using disaccharide-
structured excipients, and as seen from Table 5, the three highest ranking compounds were 
disaccharides with each excipient/protein molar ratio. Compounds such as lactitol, lactulose 
and maltitol displayed a clear trend, where an increased excipient/protein molar ratio led to 
an improvement in protein activity retention during storage, whereas altering this ratio did 
not have a clear effect when melibiose or trehalose were used. At 730:1 excipient/protein 
molar ratio, cellobiose and sucrose formulations appeared to reach a plateau in -
galactosidase activity after 30 days of storage, where further 2 months of storage did not 
reduce the activity significantly. In other formulations the decreasing activity trend continued 
throughout the whole storage period. 
Excipient crystallization was most likely the cause for poor -galactosidase stability in 
mannitol and erythritol formulations, where the XRPD analyses confirmed that 
crystallization had taken place during freeze drying (data not shown). Clear signs of 
crystallization were not detected in other samples after freeze drying or storage, but small 
sample sizes meant that crystalline regions might have always not been detected. 
 
5.2.2 Factors contributing to freeze-dried -galactosidase stability 
Based on their protein activity preservation efficacies (Fig. 12) and physical properties 
(Table  2  in  chapter  2.5.1),  the  excipients  studied  here  could  be  roughly  divided  into  three  
categories. The first category included polyalcohols with low Tg (< 15°C), namely mannitol 
and erythritol, which were not effective in protecting -galactosidase due to their high 
crystallization tendency. The second category included compounds with intermediate Tg (15 - 
80°C), which displayed a molar ratio -dependent inhibitory effect on activity loss. These 
included isomalt, isomaltulose, lactitol, lactulose, maltitol and sucrose. The third category 
included high Tg (> 100°C) compounds melibiose and trehalose, which appeared equally 
effective with all concentrations used. Despite its high Tg of 108°C (Table 2), cellobiose was 
not effective at 730:1 excipient/protein molar ratio, so it could not be included in the third 
category. Furthermore, the efficacies of isomalt and isomaltulose in upholding the enzymatic 
activity of -galactosidase were not very clearly dependent on their molar ratios, but their 
low/intermediate Tg values meant that they could not be included in the third category. 
 






Figure 12. Relative activity of freeze-dried -galactosidase (concentration before freeze 
drying 0.5 mg/ml) during storage at 45°C. when using different excipients with 730:1 (gray 
line), 7300:1 (dashed line) or 15000:1 (black line) excipient/protein molar ratios before freeze 
drying. 
 
On the basis of the results, cellobiose, melibiose, sucrose and trehalose were selected 
for further studies. The reasons for their differing properties in inhibiting the enzymatic 
activity loss of -galactosidase during storage could not be elucidated based on the data 
available, meaning that additional experiments were required. Furthermore, it was necessary 
to assess whether other protein properties besides enzymatic activity were affected by storage 












Table 5. The rank order of relative -galactosidase activities after 90-day storage at 45°C, 
when using different cryo-/lyoprotecting excipients with different excipient/protein molar 
ratios  (E/P),  with  standard  deviations  (for  samples  from  three  different  vials)  given  in  
brackets. 
 
Rank E/P = 730:1 E/P = 7300:1 E/P = 15000:1 
 excipient Rel. act. (%) excipient Rel. act. (%) excipient Rel. act. (%) 
       
1 melibiose 64 (± 3) sucrose 66 (± 3) melibiose 70 (± 4) 
2 trehalose 56 (± 2) cellobiose 63 (± 3) cellobiose 66 (± 2) 
3 cellobiose 52 (± 3) melibiose 62 (± 1) sucrose 66 (± 2) 
4 isomalt 51 (± 2) isomaltulose 58 (± 3) maltitol 65 (± 3) 
5 isomaltulose 51 (± 1) trehalose 58 (± 3) isomaltulose 64 (± 1) 
6 sucrose 50 (± 3) isomalt 57 (± 2) lactulose 62 (± 2) 
7 lactulose 33 (± 2) maltitol 53 (± 1) isomalt 60 (± 0) 
8 maltitol 33 (± 1) lactulose 52 (± 1) lactitol 59 (± 1) 
9 lactitol 27 (± 4) lactitol 48 (± 1) trehalose 57 (± 1) 
10 mannitol 2 (± 1) mannitol 3 (± 0) mannitol 1 (± 0) 
11 erythritol 0 (± 0) erythritol 0 (± 0) erythritol 0 (± 0) 
       
 
 
5.3 The effect of disaccharide physical properties on protein secondary 
structure retention during storage (I, II) 
 
The secondary structure alterations of -galactosidase during storage in different 
disaccharide formulations were investigated in order to compare whether similar changes 
took place during storage as indicated by the activity analyses. It was hypothesized that 
despite their similar molecular structures, differences in the physical properties of the four 
disaccharides of interest might play an important role in protein stability. Therefore, water 
sorption, crystallization and water plasticization tendencies of pure disaccharides in 
amorphous state were also studied at different relative humidity atmospheres.  
 
5.3.1 Changes in -galactosidase secondary structure during storage 
The efficacies of trehalose, melibiose, cellobiose and sucrose (molecular structures 
shown in Figure 13) in inhibiting the secondary structure alterations in -galactosidase were 
compared during storage at 45°C. For this purpose, lyophilizates with 730:1 excipient/protein 
molar ratio were analyzed using FT-IR during a storage period of 90 days. Figure 14 shows 
the score plot and Figure 15 the loadings plot of the three component PLS model, which was 
generated from the resulting spectra at 1720 – 1490 cm-1 region. This wave number region 
displays the so-called amide I and II absorption peaks, which result mainly from C=O 
stretching and N-H vibrations, respectively (Muga et al., 1993). It is therefore a region of 
interest when observing differences in the amide bond vibrations, which are related to 
protein secondary structure alterations.  
 
 






Figure 13. The molecular structures of trehalose, cellobiose, melibiose and sucrose. Copyright 




Figure 14. PLS score plot of FT-IR spectra, which were taken during the 90-day storage 
period at 45°C from -galactosidase lyophilizates (n = 5, 730:1 excipient/protein molar ratio). 
Copyright © (2011) Springer Ltd., reprinted with permission. 
 




The score plot (Fig. 14) suggests that -galactosidase secondary structure underwent 
similar perturbations in all four formulations during storage up to 30 days, as the points 
representing the three PCs of the spectra are clustered. However, after storing the 
lyophilizates for 90 days the PC values of trehalose and melibiose were separated from the 
cluster of sucrose and cellobiose, which on the other hand remained relatively unchanged 
from day 30 PCs. While these results did not allow the quantitation of protein secondary 
structure alterations in different formulations, the FT-IR analyses did display a similar trend 
as the enzymatic activity measurements (Fig. 12). In those the relative activity did not 
decrease significantly in sucrose and cellobiose lyophilizates after storing them for 30 days at 
45°C. In trehalose and melibiose lyophilizates, however, -galactosidase activity was still 
decreasing after 30 days of storage.  
The loadings plots (Fig. 15) were used to interpret the secondary structure alterations, 
which were most likely causing the changes observed in the FT-IR spectra during storage. 
The first significant region of variance in PC1 was found around 1640 cm-1, between the 
absorption regions of -sheet (  1635 cm-1)  and  -helix  (  1650  cm-1) structures, possibly 
denoting a transition from the former structure to the latter. The second location where an 
increase in absorption was observed was located in the -helix region at 1650 cm-1. 
Additionally, less clear structural alterations were also observed around -turn (1690 – 1665 
cm-1), distorted -structure (  1615 cm-1) and combined -helix and -structure (1560 – 1520 
cm-1) regions. The general conclusion that could be drawn from the spectra was that the 
portion of -helix structures increased, possibly at the expense of -sheet structures. Similar 
structural perturbations have been shown to occur in -galactosidase when it has been 
thermally denatured in solutions containing SDS (Muga et al., 1993). 
These results supported the enzymatic activity analyses (730:1 excipient/protein molar 
ratio) of -galactosidase. After 30 days of storage, the decrease in enzymatic activity and 
change in secondary structure seemed to stop in sucrose and cellobiose formulations, but 
they both continued in trehalose and melibiose formulations. On the other hand, the 
enzymatic activity loss was less significant in trehalose and melibiose formulations during the 
first 30 days of storage. Such trend was not visible in the secondary structure analyses, but 
the quantitation of structural alterations was not attempted in these studies, as it may be 
considered unreliable in many cases (Surewicz et al., 1993). It was hypothesized that the 
differences in the protein-protecting efficacies of the disaccharides studied here might have 
caused differences in their crystallization tendencies, as similar effects were observed in the 
case of erythritol and mannitol. Proof regarding such differences was sought by comparing 
the physical stabilities of pure disaccharides under different experimental conditions. 
 





Figure 15. PLS loadings plots of FT-IR spectra, which were taken during the 90-day storage 
period at 45°C from -galactosidase lyophilizates with 730:1 excipient/protein molar ratio. 
Protein secondary structures absorbing at given wavenumber regions have been interpreted 
according to  literature  (Arrondo et  al.,  1989;  Cooper  and Knutson,  1995;  Dong et  al.,  1990;  
Muga et al., 1993) Copyright © (2011) Springer Ltd., reprinted with permission. 
 
5.3.2 Water sorption and crystallization kinetics in pure amorphous disaccharides 
Pure freeze-dried disaccharides were equilibrated at different relative humidity 
atmospheres and their water sorption/desorption rates and crystallization onset times 
compared as shown in Figure 16. During the 500 h storage period, crystallinity was detected 
in cellobiose at RH  23%, in sucrose at RH  33%, in trehalose at RH = 43% and not at all in 
melibiose. Still, it did appear that crystallization was initiated in trehalose and melibiose 
samples at RH 33% after approximately 300 h, as their water contents began to decrease, but 
this occurred in such small scale that it could not be detected by the XRPD. A clear melibiose 
monohydrate diffractogram was acquired only after the samples had been stored at RH 43% 
for 1100 h (data not shown). When comparing the other x-ray diffractograms to those 
acquired from CSD, cellobiose and sucrose were shown to crystallize as anhydrates and 
trehalose as partly dihydrate and partly -anhydrate. 
All lyophilizates collapsed quickly when stored at RH 43%, and in case of sucrose this 
also occurred at RH 33%. Furthermore, it was clear that cellobiose crystallization had 




commenced after 91 h storage at RH 33%, but unlike sucrose, the lyophilizate did not collapse 
macroscopically. The slower crystallization rate of amorphous melibiose compared to 
trehalose was also verified by using IMC, where the latter exhibited almost an instantaneous 
crystallization at RH 60%, whereas the crystallization rate of the former was slow even at RH 




Figure 16. The water contents (%-w/w) of trehalose (A), sucrose (B), melibiose (C) and 
cellobiose  (D)  during  storage  at  RH 0  –  43% (n  =  4).  The  first  time points  where  crystalline  
regions were detected with XRPD are marked with circles. Copyright © (2012) Springer Ltd., 
reprinted with permission. 
 
5.3.3 The plasticizing effect of water sorption on the molecular mobility of pure 
disaccharides  
The  GT  and  BET  model  results  are  shown  in  Figure  17  and  Table  6.  The  table  also  
includes the critical water content values [Ccrit(H2O)], where lyophilizate Tg was depressed to 
match the storage temperature (25°C). The water content values of RH 43% were not used in 
the BET models, as including them resulted in poor model fits. This coincided with exceeding 
Ccrit(H2O) for trehalose, melibiose and cellobiose, and was relatively close in the case of 
sucrose, implying that lyophilizate collapse resulted in a change in its water sorption 
behavior. Furthermore, the results at RH 43% could not be reliably used to model the 
sorption tendencies, as all disaccharides discounting melibiose started to crystallize relatively 
quickly under those conditions, which tended to affect their water contents. 
 






Figure 17. The measured Tg (black  circles,  n  =  3)  and  water  content  (gray  squares,  n  =  4)  
values of trehalose (A), sucrose (B), melibiose (C) and cellobiose (D), as well as their GT (black 
line) and BET (gray line) fits.  The GT and BET fits are dashed above the aw range where the 
measurement values were no longer used in model fitting. Copyright © (2012) Springer Ltd., 
reprinted with permission. 
 
Trehalose, melibiose and cellobiose displayed classic type II sorption isotherms in the 
BET plots with relatively high C-values (Table 6), which are characteristic for amorphous 
compounds. On the other hand, less intense water sorption was observed in the isotherm of 
sucrose at low aw, and as a result, its C-value was considerably lower. The m0-values of all 
disaccharides were quite comparable, which could be interpreted to mean that the quantity of 
available water binding sites in the lyophilizates were close to equal. The measured Tgs of 
cellobiose and sucrose deviated more from the GT model than those of trehalose and 
melibiose, which affected their K-values. The reason for these poor fits were unknown, but a 
similar observation for sucrose has been made in another study as well (Hancock  and 
Zografi, 1994). In that case, the authors concluded that the nature of the interactions between 
sucrose and water affect the free volume of the mixture differently than with other 
disaccharides, resulting in a lower Tg value than what  is  predicted by the GT model.  There  
were some differences between the measured K-values and those found in literature, but this 
have been found to be common in case different measurement parameters have been used 
(Frank, 2007). The C-values are rarely reported in literature, and the measured value for 
trehalose differed significantly from what has been reported elsewhere (Zhang  and Zografi, 








Table 6. The  GT and BET model  parameters  measured  (meas.)  or  acquired  from literature  
(lit.) for the disaccharides studied, as well as the critical water contents [Ccrit (H2O), %-w/w], 
where Tg = 25°C. GT models were used to predict the Ccrit (H2O) values for other disaccharides 
except  for  sucrose,  where  a  2nd order polynomial fit of the measured Tg values was used 
instead. 
 
  Tg (dry)  K  m0 C Ccrit (H2O) 
disaccharide meas. lit. meas. lit. meas. lit. meas. lit. meas. 
          
cellobiose 108°C 77°C (1) 7.1 - 4.8 - 9.5 - 6.9 % 
melibiose 100°C 95°C (2) 5.4 6.1 (4) 5.0 - 9.3 - 8.0 % 
sucrose 74°C 70°C (2) 4.2 5.1 – 5.2 (5) 5.0 7.5 (6) 3.7 - 5.4 % 
trehalose 119°C 121°C (3) 6.0 5.4 – 5.8 (5) 5.4 6.4 (7) 12.2 5.0 (7) 8.9 % 
          
 
References: (1): Costantino et al. (1998), (2): Orford et al. (1990), (3): Hinrichs et al. (2005), 
(4): Roos (1997), (5): Frank (2007), (6): Wang et al. (2009), (7): Zhang and Zografi (2000). 
 
The structural relaxation times of two of the most physically stable disaccharides (i.e. 
trehalose and melibiose) were studied as a function of water content by using ssNMR. In 
Figure 18 an increase in water content is denoted by an increase in T / Tg, and the results 
indicated that the T1H  of  melibiose  was  higher  than  that  of  trehalose  at  a  given  Tg. As 
molecular mobility decreases with increasing relaxation rates, longer relaxation time was an 
indication of more restricted hydrogen mobility.  
 
 
Figure 18. The change in T1H of trehalose (black circles) and melibiose (white squares) as a 
function of Tg. Copyright © (2012) Springer Ltd., reprinted with permission. 
 
5.3.4 Consequences of physical stability differences between excipients 
The results of these experiments offered some possible explanations for the differences 
in -galactosidase storage stabilities in different formulations. Cellobiose and sucrose were 
shown to inhibit protein activity loss less effectively than melibiose and trehalose at low 




excipient concentrations (Fig. 12), and a similar division was observed regarding the 
crystallization tendencies of the disaccharides (Fig. 16). Using 730:1 excipient/protein molar 
ratio in the -galactosidase studies resulted in lower lyophilizate mass (< 2 mg) than with 
7300:1 (> 10 mg) or 15000:1 (> 20 mg) molar ratios. The initial average water content of the 
730:1 molar ratio lyophilizates was also higher (  2.7 %-w/w) than that of 7300:1 (  1.6 %-
w/w) or 15000:1 (  1.3 %-w/w) molar ratio lyophilizates, and the water contents may have 
increased during storage. Higher water content could have led to a higher excipient 
crystallization rate in the samples with 730:1 excipient/protein molar, especially in the case 
of the relatively easily crystallizing compounds cellobiose and sucrose. However, small 
crystalline regions might have gone unnoticed in the XRPD analyses in such low mass 
lyophilizates (m < 2 mg). The underlying causes for the pronounced crystallization 
tendencies of cellobiose and sucrose were not certain, but in the case of sucrose its relatively 
low Tg (  74°C) meant that its Ccrit(H2O) was clearly lower than with the other disaccharides. 
Crystallization usually proceeds more quickly at Tg < T < Tm, and a lower water content was 
therefore necessary to depress its Tg below storage temperature. On the other hand, the water 
solubility of cellobiose has been shown to be relatively low compared to other sugars (Gray et 
al., 2003), and compounds with low aqueous solubility have sometimes been observed to 
possess a high crystallization tendency from the amorphous state (Roos, 1993). 
The lower hydrogen mobility of melibiose could be one of the reasons why it was shown 
to crystallize later than trehalose when stored at RH 43%. Furthermore, the higher T1H of 
melibiose might also have been an indication of its ability to form a glass matrix which 
restricted the mobility of -galactosidase more effectively than trehalose. However, these 
were only some of the possible reasons for the differences between the cryo-/lyoprotecting 
efficacies of the two compounds. It was therefore necessary to study the protein-protecting 
efficacy of melibiose using another model protein, and to estimate whether the freeze drying 
process itself affects protein stability. 
 
 
5.4 Studying the effect of freeze drying parameters and formulation on IgG 
stability (III) 
 
Before carrying out further storage stability experiments, it was necessary to find out 
whether the freeze drying process had an effect on protein stability. Even though there is 
considerable evidence to suggest that exceeding Tg’  or  Tg during drying may not negatively 
affect the stability of some IgGs (Sarciaux et al., 1999; Schersch et al., 2010; Schersch et al., 
2012), protein degradation might still occur if the formulation is not optimal (Izutsu et al., 
1994). Therefore, potential hazards for polyclonal IgG stability during freeze drying were 
assessed by altering the processing conditions, namely primary drying pressure (Pprim) and 
secondary drying heating rate ( Tsec), as well as the formulation composition. 
 
5.4.1 Varying the processing conditions 
Figure 19 shows the effect of Pprim and Tsec on product temperature during drying. 
Lowering the chamber pressure had a clear decreasing effect on sample temperature during 
primary drying due to an increase in sublimation rates. Heating the shelves at either 30°C/h 
or 60°C/h during secondary drying caused the samples to heat at relatively comparable rates, 
whereas using Tsec of 5°C/h resulted in relatively low sample heating rate. When using 
higher Pprim, collapses were observed in some samples (Fig. 20), and the average residual 




lyophilizate water content was lower when dried at Pprim = 20 mTorr (2.6 ± 0.2%-w/w) than 
at  Pprim  =  100  mTorr  (3.3  ±  0.5%-w/w).  The  PLS  model  formed  from  the  water  content  
results confirmed that Pprim had a statistically significant effect on residual lyophilizate 
water contents (p < 0.05). This suggested that ice sublimation was not always completed at 
the end of primary drying when using higher Pprim, because otherwise all samples should 
have contained similar amount of water at the end of primary drying. This may have caused 
the collapses to occur in some samples (Fig. 20), as the shelf temperature was increased 
during secondary drying while some samples still contained ice crystals. 
 
 
Figure 19. The  effect  of  Pprim  and  Tsec  on  average  sample  temperature  (±  SD),  when  
measured with thermocouples. The Tg’  of  the  formulation  (-32°C)  is  marked  with  a  dashed  
gray horizontal line, and shelf temperatures are shown as straight black, blue and red lines. 
 
The effects of freeze drying parameters on polyclonal IgG stability were analyzed with 
in vitro binding activity analysis by using ELISA, by measuring MRE changes at 217 nm 
wavelength with CD, by measuring Z-ave and PDI with DLS, and by measuring changes in 
soluble IgG monomer content with AF4. In order to check whether there were statistically 
significant changes in the responses due to freeze drying parameters, PLS models were 
created from the measurement results. The Q2 and R2 values for each response are shown in 
Table 7. Q2 is generally considered a better indicator for model validity than R2, because the 
goodness of fit may be increased simply by making the model more complicated, whereas this 
does not automatically result in better goodness of prediction. The Q2 values of Z-ave and 
PDI indicate that the prediction accuracies of these models were relatively high, as does 
Figure 21, where the measured average Z-ave and PDI values are shown along with the 
calculated models. The figure shows that drying the IgG samples with lower Pprim resulted 
in significantly higher Z-ave and PDI (p < 0.01), which may have been caused by increased 
protein aggregation. The effect of Tsec on these responses was not statistically significant. 
The lack of fit regarding the other responses may have indicated that either Pprim and Tsec 
did not have any measurable effect on MRE at 217 nm wavelength, IgG monomer content or 
its in vitro binding activity, or then the measurement methods were not accurate enough. 
 





Figure 20. Lyophilizates dried with a Pprim of 20 mTorr (left),  60 mTorr (center) and 100 
mTorr (right). 
 
Table 7. Evaluation of PLS model responses (analysis techniques shown in brackets) based on 
their goodness of fit (R2) and goodness of prediction (Q2) values. 
 
  %-act. (ELISA)  MRE 217 nm (CD) Z-ave (DLS) PDI (DLS) Monomer-% (AF4) 
      
R2 0.06 0.37 0.64 0.81 0.23 
Q2 0.00 0.06 0.60 0.75 0.00 





Figure 21. The  effect  of  Pprim  and  Tsec  on  Z-ave  (left)  and  PDI  (right)  of  rehydrated  
lyophilizates, when measured with DLS. The grids show the PLS-predicted effect of 
formulation parameters and the black dots the measured responses, while the gray lines depict 
the model deviation from measured values. 
 




5.4.2 Varying the formulation composition 
In  order  to  identify  possible  causes  for  the  effect  of  Pprim  on  IgG  aggregation,  the  
formulation composition was varied. Figure 22 depicts the effect of drying different 
formulations at  either  Pprim = 20 mTorr  or  100 mTorr.  Including NaCl  in  the formulation 
caused a clear decrease in both Z-ave and PDI compared to using only trehalose and BSA as 
protective excipients. Furthermore, using Na-phosphate buffer was shown to increase Z-ave 
and PDI when drying at Pprim = 100 mTorr. Since sample temperature during drying was 
shown to decrease as a function of Pprim (Fig. 19), it is possible that physical state of Na-
phosphate buffer was affected by the sample temperature. Even Na-phosphate buffers as 
dilute as 1 mM have been shown to crystallize as Na2HPO4·12H2O when frozen to -50°C 
(Varshney et al., 2006). On the other hand, another component of the buffer, NaH2PO4, may 
remain amorphous during freezing in formulations containing several solutes, in which case 
it  has  a  Tg’ of -45°C (Chang and Randall, 1992). It is therefore possible that when the 
formulations containing Na-phosphate buffer were first frozen at -40°C, the freeze 
concentration of NaH2PO4 was not complete if the buffer was excluded as its own amorphous 
phase. Drying at Pprim = 20 mTorr cooled the samples temporarily to approximately -48°C 
(Fig. 19), which may then have resulted in additional freeze concentration and buffer 
crystallization compared to drying at higher pressure. This may have resulted in more 
pronounced change in the physical state of the Na-phosphate buffer (i.e. from amorphous to 
crystalline), and subsequently altered protein conformation. However, the verification of 
buffer crystallization from the lyophilizates was not successful, because crystalline as 
Na2HPO4·12H2O tends to become amorphous when it is dehydrated during primary drying 
(Pyne et al., 2003). Another possible reason for the effect of formulation parameters on Z-ave 
and PDI is that the excipients affected the amount of air bubbles that were formed during 
rehydration, but this should not have accounted for the difference observed as a function 




Figure 22. The  effect  of  formulation  and  processing  parameters  on  Z-ave  (left)  and  PDI  
(right). The black bars represent freeze drying with Pprim = 20 mTorr and the gray bars with 
Pprim = 100 mTorr, with Tsec being 5C°/h in both cases. 
 
5.4.3 Factors to be taken into account when freeze drying IgG-class proteins 
Product collapse did not seem to result in decreased polyclonal bovine IgG stability 
immediately after freeze drying. Furthermore, longer holding time at 40°C during secondary 




drying (i.e. using higher Tsec) did not cause considerable monomer loss, aggregation or 
secondary structure alterations. Freeze drying parameters only appeared to have an effect on 
polyclonal IgG stability when a crystallizing excipient (Na-phosphate buffer) was used in the 
formulation. Therefore non-crystallizing buffers should be preferred. Here increasing the 
lyophilizate residual water content (at 2.5 – 3.3%-w/w interval) did not lead to increased 
protein degradation, but this does not mean that changes in protein structure could not have 
occurred with lower or higher water contents than this. Including NaCl in the formulation 
reduced average particle size and polydispersity in the rehydrated solutions. This could have 
been caused by its effect on the protein surface potential, but perhaps a more likely cause was 
that a smaller number of air bubbles were formed during lyophilizate rehydration when NaCl 
was used in the formulation. 
Changes in the Z-ave and PDI of rehydrated samples seemed to be more clear 
indicators of IgG instability compared to secondary structure alterations, monomer loss or in 
vitro binding activity. This was to be expected, since aggregation tends to be a common 
response to many different types of stresses in IgG-class proteins (Hawe et al., 2009; 
Thirumangalathu et al., 2009; Tyagi et al., 2009). It is also recommended to use several 
orthogonal analysis techniques in protein stability studies to properly characterize the 
properties of the aggregates that have been formed (Carpenter et al., 2010). 
 
 
5.5 Comparing the efficacies of trehalose and melibiose as cryo-/lyo-
protecting excipients for rituximab during freeze drying and storage (IV) 
 
Further comparison between the protein-protecting efficacies of trehalose and 
melibiose was carried out by freeze drying rituximab, a chimeric mouse/human IgG1  mAb, 
while using either of the two disaccharides as cryo-/lyoprotecting excipients. Rituximab used 
in the study is marketed with the trade name MabThera® (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland), which is used in the treatment of Non-Hodgkin lymphoma, chronic 
lymphocytic leukemia and severe rheumatoid arthritis. One topic of interest in the 
experiments was to find out whether the water content of the lyophilizates affects rituximab 
stability during storage, and to take this into consideration, the lyophilizates were stored in 
loosely stoppered vials at different relative humidity atmospheres.  
 
5.5.1 Protein purification and lyophilizate physical properties 
In addition to the API, MabThera® also contains 7.35 mg/ml sodium citrate, 9 mg/ml 
sodium chloride and 0.7 mg/ml PS80 as excipients, and the removal of the original 
formulation excipients was carried out with size-exclusion fractionation columns. However, 
the PS80 quantitation measurements after fractionation showed that the process did not 
completely purify the surfactant from the solution, removing only approximately 37% of the 
total PS80 content. Therefore, the solutions contained 1 mg/ml rituximab, 50 mg/ml 
disaccharide (either trehalose or melibiose), 10 mM Na-citrate buffer (pH 6.3) and 0.033 
mg/ml Ps80 before freeze drying. 
The lyophilizate water contents and Tgs before and after storage at different relative 
humidity atmospheres are shown in Table 8. Storage at RH 5% did not lead to clear changes 
in water content or Tg, but increased water content at RH 11% and 23% resulted in greated Tg 
depression due to water plasticization. Tg was not exceeded in either formulation during 
storage, and no lyophilizate collapses were observed. Similarly, excipient crystallization was




not detected with XRPD in the lyophilizates during storage at any relative humidity 
atmosphere when analyzed monthly (data not shown). 
 
Table 8. Water contents and glass transition temperatures (Tg) of lyophilized trehalose and 
melibiose formulations before and after the 90-day storage under different relative humidity 
atmospheres. The water content measurement standard deviations before storage for 
trehalose and melibiose formulations were ±0.3% and ±0.1%, respectively. 
 

























         
trehalose 2.3% 2.5% 4.1% 5.9% 91°C 90°C 74°C 56°C 
melibiose 2.1% 2.3% 3.7% 5.9% 82°C 86°C 67°C 57°C 
         
 
5.5.2 Effects of freeze drying and storage on rituximab structure and sample particle 
contents 
Freeze drying caused clear alterations in rituximab CD spectra, especially in the 190 – 
200 nm wavelength region (Fig. 23). According to literature, these spectral changes may be 
attributed to an increase in the protein -helix content (MRE intensification around 190 – 
200 nm), as well as to a decrease in anti-parallel -sheet content (MRE intensification at 218 
nm) (Kelly et al., 2005). The changes in the 190 – 200 nm wavelength region were more 
pronounced in the trehalose formulation. Freeze drying and rehydration also increased the 
amount of < 2 µm diameter particles in the LO analyses (Fig. 24, A) in both formulations, but 
the increase in particle concentration was more significant in the trehalose formulation. 
Similarly, drying and rehydration increased the amount of < 1 µm diameter particles in the 
NTA analyses from 0.1*109 (± 0.02*109) particles per container before freeze drying to 
1.0*109 (± 0.5*109) and 0.4*109 (± 0.2*109) particles per container in the trehalose and 
melibiose formulations, respectively. When analyzed with DLS, the rituximab solution before 
freeze  drying  had  Z-ave  of  12  ±  0.7  nm  and  PDI  of  0.3  (±  0.0).  Drying  and  rehydration  
increased Z-ave and PDI in both trehalose (Z-ave 82 ± 16 nm, PDI 1.0 ± 0.0) and melibiose 
formulations (Z-ave = 14 ± 0.2 nm, PDI = 0.4 ± 0.0), but the effect was much less intensive in 
the latter. The particle analysis methods (LO, NTA and DLS) cannot be used to analyze 
particle composition, so it is not known whether they consisted of aggregated protein, silicon 
oil or air. Therefore, the particle counts and sizes measured with these techniques may not 
represent the actual protein aggregate contents of the rehydrated solutions. It should also be 
noted that even though LO is sometimes used to quantify > 1 µm particles (Hawe et al., 
2009), it has been stated that the method might be inaccurate for the analysis of particles < 2 
µm (Singh et al., 2010). 
 





Figure 23. CD  spectra  of  rituximab  before  and  after  freeze  drying  in  trehalose  (left)  and  
melibiose (right) formulations, and after storage at RH 5% (upper ) or RH 23% (lower) for up 




Figure 24. >  1  µm  particle  counts  (measured  with  LO)  in  trehalose  and  melibiose  
formulations. A: The effect of freeze drying on particles counts and size distributions 
(logarithmic particle size scale). B-D: The effect of storage at different relative humidity 
atmospheres on particles counts. Copyright © (2013) Wiley-Blackwell Ltd., reprinted with 
permission. 




HP-SEC analyses (Fig. 25) indicated that a small amount of rituximab fragments with 
Mw  80  and  30  kDa  (elution  times  approximately  25  and  26  min)  were  present  in  the  
formulations after freeze drying. Based on their molar masses, these fragments may have 
consisted of one heavy and one light IgG chain (Mw  80 kDa) and a single light chain (Mw  
30 kDa). Based on the fluorescence detector results, the concentration of rituximab 
fragments with Mw  30 kDa was 0.9% ± 0.02% in the trehalose and 0.03% ± 0.002% in the 
melibiose formulation of the total recovered rituximab content after freeze drying. This 
suggested that freeze drying in the presence of trehalose caused more rituximab 
fragmentation. SDS-PAGE analyses confirmed the presence of these fragments before and 
after freeze drying in both formulations (data not shown), but their concentrations could not 
be compared due to the semi-quantitative nature of the method. 
 
 
Figure 25. HP-SEC fluorescence detector signals of rituximab before and after freeze drying 
in  trehalose  (TRE)  and melibiose  (MEL)  formulations,  and after  90-day storage  at  RH 23%.  
The molar mass values have been calculated from UV and MALLS signals. Copyright © (2013) 
Wiley-Blackwell Ltd., reprinted with permission. 
 
During storage, the concentration of > 1 µm diameter particles remained generally 
higher in the trehalose than in the melibiose formulation (Fig. 24, B-D), even though the 
particle counts appeared to decrease in the trehalose formulation during storage at RH 11% 
and 23%. The < 1 µm particle counts increased clearly in the trehalose formulation when 
stored at RH 5% and 11%, whereas only a small increase was observed in the melibiose 
formulation at RH 5% (Fig. 26). It is noteworthy that in the case of specifically particle-rich 
samples (e.g. in trehalose formulation samples that were stored at RH 5% for 30 days or 
longer), the solutions analyzed with NTA had to be diluted before measurement. This may 
have contributed to measurement error, because the sample dilution may break down protein 
aggregates or create new ones, or lead to air bubble formation. Still, the secondary structure 
changes were aggravated more in both formulations when stored at RH 5% than when stored 
at RH 23% (Fig. 23). The HP-SEC and SDS-PAGE analyses did not show significant changes 
occurring in either formulation, but the recovered 30 kDa fragment content appeared to 
decrease  from  0.9%  to  0.6%  (±  0.02%)  in  the  trehalose  formulation  during  storage  at  RH  
23%. No changes in SDS-PAGE results were observed during storage (data not shown). 
 






Figure 26. <  1  µm  particle  counts  (measured  with  NTA)  in  trehalose  (left)  and  melibiose  
(right) formulations during storage at different relative humidity atmospheres. Copyright © 
(2013) Wiley-Blackwell Ltd., reprinted with permission. 
 
5.5.3 Factors affecting rituximab stability during and after drying 
It was found that there were clear differences in rituximab stability during freeze drying 
depending on whether trehalose or melibiose was used as the cryo-/lyoprotecting excipient. 
The more significant rituximab aggregation, fragmentation and secondary structure 
alteration behavior observed in the trehalose formulation was not caused by differences in 
lyophilizate water contents between the two formulations. However, the storage stability 
studies at RH 5%, especially the CD and NTA results, indicated that rituximab storage 
stability was poor with relatively low lyophilizate water contents (  2-3 %-w/w) compared to 
when the lyophilizate water content was higher. This coupled with the intense secondary 
structure alterations observed in both formulations as a result of freeze drying might mean 
that the protein was susceptible to drying-induced instability. Similar results regarding 
freeze-dried mAb stability in low residual water content lyophilizates have sometimes been 
observed. For example, a certain IgG1 class protein was shown to exhibit decreased storage 
stability in lyophilizates with water content below 3% (Chang et al., 2005). On the other 
hand, the storage stability of another mAb seemed to be relatively unaffected by the 
lyophilizate water content at 1 - 8.4% interval (Cleland et al., 2001). Therefore it is likely that 
the effect of low water content on mAb storage stability is dependent on the protein in 
question.  
The analytical techniques used here could not show that storage at higher relative 
humidity atmospheres would have resulted in increased rituximab degradation. If anything, 
the  storage  stability  of  the  protein  seemed  to  be  better  at  RH  23%  than  at  RH  5%  in  both  
formulations. However, the analytical methodologies used here might not have been accurate 
enough to detect small concentrations of Maillard reaction byproducts, and analysis methods 
capable of detecting changes in protein glycation, such as those developed by Fisher et al. 
(2008),  should  be  additionally  employed  in  future  studies.  It  is  also  likely  that  Maillard  
reaction would become a more important degradation route for rituximab at a higher 
temperature or humidity than what was used in these studies. Still, the st0rage conditions 
used here can still be considered more stressed than what marketed lyophilizates are 
normally subjected to before administration to patients. This is because commercial freeze-
dried products would rarely contain such water contents as seen here (up to 6%-w/w), as the 
primary package protects the product from moisture uptake. Here the vials were stored 
loosely stoppered so that water sorption could occur. The storage conditions were chosen so 




that they would not induce lyophilizate collapse due to the depression of Tg below the storage 
temperature, because reaction kinetics at T > Tg might not represent those at T < Tg. While 
the ICH guideline Q5C on the stability testing of biotechnological products suggests that 
accelerated storage stability studies are important for pinpointing potential hazards for the 
stability of protein drug products, it also states that their actual expiration times should be 
defined based on real-time data at intended storage conditions (ICH, 1995). Therefore, 
Maillard reaction kinetics studies conducted at elevated temperatures might not correspond 
with the actual shelf life of a rituximab drug product containing melibiose.  
 
 
5.6 Using melibiose as a freeze drying excipient (I, II, IV) 
 
Prior to these experiments, there were no published studies available where melibiose 
(6-O- -D-galactopyranosyl-D-glucopyranose) would have been used to protect proteins from 
degradation during freeze drying and the subsequent storage. Also, there was very little 
information on its stability in amorphous state. Here, the cryo-/lyoprotective efficacy of 
melibiose was shown to be comparable to trehalose when using -galactosidase as the model 
protein (I), or better when using rituximab (IV).  
One reason for this may have been the physical stability of amorphous melibiose. Its 
crystallization rate in room temperature with water contents up to  10%-w/w was shown to 
be relatively slow compared to cellobiose, sucrose and trehalose (II). The molecular mobility 
of amorphous melibiose (determined based on T1H) was also slower than that of trehalose, 
when the Tgs of the disaccharide/water mixtures were comparable. This means that the 
amorphous matrix which melibiose forms around proteins during the freezing step might be 
relatively viscous and stable, which could effectively inhibit protein unfolding and reactivity.  
On the other hand, the studies conducted with rituximab (IV) suggested that melibiose 
may have been more effective than trehalose in protecting rituximab from degradation under 
dry conditions (RH 5%). Therefore its efficacy in partially substituting water as a hydrogen 
bond former with hydrophilic protein surface moieties may have been better than that of 
trehalose. The hydrogen bond formation tendencies of different disaccharides can be 
assessed to some degree based on their molecular structures. As shown in Figure 13 (chapter 
5.3.1), the molecular structure of melibiose differs from that of trehalose in two distinct ways. 
While trehalose is formed of two glucose units (linked together by an -1,1 glycosidic bond), 
melibiose consists of one glucose and one galactose unit (connected by an -1,6 glycosidic 
bond). Secondly, the glycosidic bond in melibiose connects to the exocyclic methyl alcohol 
group of the glucose subunit, creating a two-carbon atom bridge between the 
monosaccharide rings, whereas this bridge consists of only one carbon atom in many of the 
other disaccharides studied here. Interestingly, isomaltulose (6-0- -D-glucopyranosyl-D-
fructose) consists of glucose and fructose subunits linked together by a similar -1,6 
glycosidic bond as in melibiose. As can be seen from Figure 12 (chapter 5.2.1), isomaltulose 
was also effective in protecting -galactosidase from activity loss, despite being a reducing 
disaccharide with a relatively low Tg (Table 2, chapter 2.5.1). Whether such a two-carbon 
atom bridge between the monosaccharide subunits results in improved protein protective 
efficacy can only be speculated at this point. However, it might improve the flexibility of the 
disaccharide backbone, allowing an increased number of hydroxyl groups in a single 
molecule to form hydrogen bonds with protein surface moieties compared to a more rigid 
molecule. Additional studies are necessary to evaluate whether such structural properties can 
affect the cryo-/lyoprotective efficacies of disaccharides. 




Overall, these studies represent very early stage attempts of using excipients in freeze-
dried formulations which have not been approved by the regulatory authorities. Therefore, 
the feasibility of using melibiose in pharmaceutical protein drug products cannot be assessed 
based on these results alone. The next logical step towards proving or disproving that it could 
be used would be to analyze whether differences in protein glycation are observed when 
melibiose is used as opposed to a non-reducing disaccharide. Furthermore, despite melibiose 
being abundantly present in many commonly ingested food products such as those 
containing soy beans (Caplice and Fitzgerald, 1999), conclusive toxicity studies would be 








In this thesis several disaccharides and polyalcohols were studied as protein-protecting 
excipients in freeze-dried formulations. Based on the enzymatic activity retention studies 
carried out using -galactosidase as the model protein, disaccharides were generally better 
than polyalcohols in inhibiting activity loss during storage. One reason for this may have 
been the relatively low Tgs and high crystallization tendencies of many polyalcohols. Also, in 
the case of disaccharides, storage at high relative humidity atmospheres brought out 
differences in excipient crystallization tendencies. Despite their relatively good efficacies in 
protecting -galactosidase from activity loss during storage, sucrose and cellobiose were 
shown to crystallize more easily than trehalose and melibiose. While such a tendency would 
probably not manifest in freeze-dried protein formulations under normal storage conditions, 
storage at high temperatures or water release from vial stoppers might result in the 
crystallization of unstable excipients. 
The efficacy of melibiose as a protein-protecting excipient was not attributable only to 
its low crystallization tendency, however. Compared to trehalose, melibiose was superior in 
inhibiting rituximab degradation during freeze drying and storage in 25°C in relative 
humidity atmospheres up to 23%. Possible reasons for this include its relatively slow 
hydrogen mobility, as well as its hydrogen bond formation properties, which may allow it to 
effectively replace water on protein surfaces during dehydration. The freeze drying stability of 
rituximab was not thoroughly explored by using different formulations or freeze drying 
parameters, because the main objective was to compare trehalose and melibiose as protein-
protecting excipients. Still, these studies gave an indication that rituximab might be 
susceptible to drying-induced degradation, even though additional studies would be needed 
to assess whether this might occur in other formulations as well.  
Based on the freeze drying experiments carried out with polyclonal IgG, it could be 
hypothesized that the stability of the protein did not depend heavily on freeze drying 
parameters. However, this does not always hold true when using crystallizing excipients in 
the formulations. In the case of polyclonal IgG, different primary drying pressure or 
secondary drying heating rate did not affect protein stability unless Na-phosphate was used 
in the formulation. In that case, using a lower primary drying pressure led to an increase in 
protein aggregation, which was most likely caused by increased disodium hydrogen 
phosphate dodecahydrate crystallization. The combination of low sample temperature and 
Na-phosphate buffer should therefore be avoided. Lyophilizate collapse during freeze drying 
did not appear to affect protein stability negatively.  
These results encourage further studies on “new” freeze drying excipients. Although 
many carbohydrates have been extensively studied for other applications and are readily 
available as pure substances, the published studies regarding the use of compounds other 
than the most common ones as freeze drying excipients are scarce. Broadening the horizons 
in this field may lead to new innovations in API stabilization and processing. Instead of 
declaring certain compounds such as reducing disaccharides or easily crystallizing buffers 
unfit as excipients in certain products, it would be important to evaluate whether their 
properties affect API stability under relevant processing and storage conditions. It would also 
be interesting to examine how often accelerated stability studies correlate with actual storage 
times in the case of protein pharmaceuticals. Nevertheless, regulatory guidelines regarding 
accelerated API stability measurements must be borne in mind, because they cannot be 
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